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1  Introduction 
1.1 The ABC transporter superfamily. 
The ATP binding cassette (ABC) transporter family is one of the major 
membrane transporter families, which is present in all living organisms from 
prokaryotes to eukaryotes including animals, plants, and fungi (Holland and 
Blight 1999). It has been shown that the different members of this protein 
family can export or import molecules in an adenosine triphosphate (ATP) 
dependent fashion, and they thereby participate in various physiological 
processes. 
In prokaryotes, the transporters are generally promoting inward movement of 
nutrients and outward transport of toxic compounds (Higgins and Linton 
2001) showing the functional diversity of this transporter superfamily. 
Interestingly the outward transport of small molecular weight compounds is a 
common function to the different organisms, while the inward activity seems 
to have been eliminated during evolution, or at least to be specific to the 
kingdom of prokaryotes. As an example, the ABC transporters play various 
physiological roles by transporting molecules within the cells from cytoplasm 
to organelles. Besides their physiological relevance they are also involved in 
the export of antibiotics, antifungal agents, herbicides as well as anticancer 
drugs. This last transport activity highlights the economical and clinical 
relevance of ABC transporters. Moreover a certain number of Mendelien 
diseases are linked to the mutation of ABC transporter in Human (Dean and 
Annilo 2005) (Table 1.1). 
 
Table 1.1: examples of ABC transporters and their clinical phenotypes 
The minimal structure of ABC transporters is composed of two 
transmembrane domains (TMD) that form the pathway through which the 
molecules are transported and give substrate specificity, and two ATP or 
Nucleotide Binding Domains (NBD) associated with the cytoplasmic face of 
the membrane and which provide energy to the transport by binding and 
hydrolyzing ATP molecule. These four elements can be coded in operon 
systems in the case of prokaryotes, while a single gene in eukaryotes can 
encode them. However some half transporters exist at least in human, where 
only one TMD and one NBD are present, and therefore they function then as 
homo or heterodimers (Figure 1.1.).  
The NBD domain of the protein contains 2 walker A and B motifs that have 
been associated with ATP dependent proteins and the C motif specific to the 
ABC transporter superfamily (Walker, Saraste et al. 1982). Therefore the 
NBD domains are highly conserved among evolution and are responsible for 
the classification of transporter as ABC transporter (Higgins, Hiles et al. 
1986). It is accepted, but not really understood, that the close cooperation 
between NBD and TMD allows that an ATP binding to the NBD leads to a 
conformational change of the TMD ultimately leading to the molecule 
transport (Hollenstein, Dawson et al. 2007) (Hollenstein, Frei et al. 2007). 
 
Figure 1.1. Structural features of the ABC transporters. A. Half transporter structure as the 
ABCG2. These transporters are functional in dimers. B. Minimal structure of ABC transporter 
with two NBD and two TMD. C. MRP like structure with a supplementary L0 intracytoplasmic 
loop and an extra transmembrane domain. Figure adapted from Flora Szeri, 
Considering the fact that this report will focus on one single Human ABC 
transporter (ABCC6), I will only give a brief description of Human members 
of the ABC superfamily. Based on phylogenic and amino acid sequence 
alignment of the NBD domains, the human ABC transporters have been 
grouped into seven subfamilies. In each of the subfamily a high identity in the 
TMD organization as well as in the gene organization and the intron 
localization can be observed. However it is important to note that besides 
similarities, the functions of ABC proteins correspond poorly to the 
subfamilies and it is not rare to find two ABC proteins from two subfamilies 
sharing more similarities in substrate recognition than proteins from the same 
subfamily. The different ABC transporter subfamilies have been numbered 
from A to G. Into these 7 groups, 48 human ABC transporter members have 
been identified (Dean and Allikmets 2001) (Dean, Rzhetsky et al. 2001).  
 
The human ABC transporter subfamilies. Phylogenetic tree of the human ABC genes based on 
their ATP domains. Note that some proteins analyzed contain two ATP-binding domains (I 
and II), whereas others contain only one ATP-binding domain. (adapted from Dean 2002) 
If it is usual to see investigation of the protein function, it is important to note 
that transcriptional regulation studies have also been performed on some of the 
human ABC transporter members, usually by screening the promoter region 
for nuclear factor binding sites, and testing transcriptional activity of the gene 
after induction of specific factor by various drugs. In very few cases the 
promoter has been cloned and luciferase reporter gene assay has been 
performed to measure the promoter activity. Investigations of the methylation 
pattern of the promoter that is often linked with the activity of the gene, as 
well as epigenetic study of the gene expression were rarely performed.  
After briefly introducing the different subfamilies, I will focus on the ABCC 
subfamily that contains the ABCC6 gene, and I will finally describe a relevant 
example of ABC transporter transcriptional analysis by giving an overview of 
the transcriptional regulation of the ABCC7/CFTR gene. 
1.2 The ABC transporter subfamilies: a quick overview. 
The ABCA subfamily contains twelve full transporters that are involved for 
most of them in lipid metabolism. The most studied member of this subfamily 
is the ABCA1 transporter that is also the first described ABC transporter. 
ABCA1 has been associated with the Mendelian Tangier disease (Brooks-
Wilson, Marcil et al. 1999), characterized by dramatic level decrease in HDL-
C and Apolipoprotein A-I (Apo A-I) and accumulation of cholesteryl esters 
(CE) in tissues rich in macrophage (Oram 2000). It is however important to 
note that the significance of this disease worldwide is very limited since only 
50 cases have been identified. 
The ABCB subfamily consists of eleven transporters and interestingly it 
includes full and half transporters as well. Members of this complex subfamily 
can be found in many different compartimentalization / localization and its 
members exhibit various transport activities: bile acid secretion for ABCB4 
and ABCB11, peptide transport into the endoplasmlic reticulum and a role in 
antigen presentation for ABCB2 and ABCB3, also called TAP1 and TAP2 
respectively (Herget and Tampe 2007), iron metabolism and mitochondria 
localization for the ABCB6, ABCB7 ABCB8 and ABCB10 half transporters 
(Zutz, Gompf et al. 2009). The most studied member of this subfamily is the 
ABCB1/Pgp transporter. This transporter has an important clinical impact 
since it has been characterized through its role in cancer resistance (Sarkadi, 
Homolya et al. 2006) (Szakacs, Varadi et al. 2008). 
For the ABCC subfamily, see the section 1.3. below. 
The ABCD subfamily consists of four half transporters that are located in the 
peroxisome, and are involved in the transport of very long chain fatty acids. 
The most studied member of this subfamily is ABCD1 since mutations in the 
protein lead to the X-linked adrenoleukodystrophy genetic disorder (Mosser, 
Douar et al. 1993). By accumulation of very long chain fatty acids this 
disorder affects both the adrenal glands and the white matter of the nervous 
system (Berger and Gartner 2006). 
The ABCE and ABCF subfamilies do not have transmembrane domains, 
making their role in transmembrane transport unlikely. ABCE1 is the only 
member of the ABCE subfamily, and it has been found to block the activity of 
the ribonuclease L, and then to maybe be part of the innate immunity system 
(Vasiliou, Vasiliou et al. 2009). The ABCF subfamily contains three members 
that play a role in protein synthesis and it is believed that these proteins play a 
role in inflammatory processes (Vasiliou, Vasiliou et al. 2009). 
The ABCG subfamily consists in five half transporters. Mutations in the 
ABCG genes have been implicated in sterol accumulation disorders and 
atherosclerosis. However among members of this subfamily the 
ABCG2/BCRP/MXR is the most studied. Indeed this transporter has a clinical 
significance since it can give resistance to a wide variety of anticancer agents 
(Sarkadi, Homolya et al. 2006). 
1.3 The ABCC transporter subfamily. 
The ABCC subfamily consists of twelve full transporters with various 
functions and transport spectrums. The ABCC13 gene is often considered as a 
member of this subfamily, even if it is a pseudogene incapable of encoding a 
functional protein. In the ABCC subfamily, two different groups can be 
distinguished within the ABCC subfamily, depending on the presence of an 
additional Nterminal TMD. Indeed the short ABCC members have a structure 
with TMD1-NBD1-TMD2-NBD2, and the long ABCC members have an extra 
N terminal transmembrane domain called TMD0 connected to the core by a 
long cytoplasmic loop called L0 (Tusnady, Bakos et al. 1997) (Klein, Sarkadi 
et al. 1999). Seven proteins have the long ABCC structure, ABCC1/MRP1, 
ABCC2/MRP2, ABCC3/MRP3, ABCC6/MRP6, ABCC8/SUR1, 
ABCC9/SUR2 and ABCC10/MRP7 and are considered as long (except for the 
SUR1 and 2), and the five remaining proteins ABCC4/MRP4, ABCC5/MRP5, 
ABCC7/CFTR, ABCC11/MRP8 and ABCC12/MRP9 belong to the short 
ABCC subfamily (except for the CFTR). Interestingly the ABCC7/CFTR, the 
ABCC8/SUR1 and the ABCC9/SUR2 are not transporters. Indeed, ABCC7 is 
an ion channel while SUR1 and SUR2 are potassium channel sensors. The 
other ABCC members are involved in multidrug resistance and are designated 
as multidrug resistance-associated proteins (MRP) (Deeley, Westlake et al. 
2006). 
To date, only few promoters of ABCC transporters have been consistently 
characterized. Thus the ABCC1, ABCC2 ABCC3 ABCC6 and ABCC7 are the 
only members with deep transcriptional regulation studies. Therefore there is a 
lack of information about the regulatory elements controlling their expression.  
1.4 Example of transcriptional regulation studies on an ABCC 
transporter: ABCC7. 
Here I will give an overview of the transcriptional regulation of the 
ABCC7/CFTR gene. This gene is a relevant example of transcriptional 
regulation study in our case. Indeed, ABCC7 as ABCC6 is a member of the 
ABCC subfamily, and they share sequences similarities. Moreover both genes 
exhibit a tissue specific pattern of expression. Finally the transcriptional 
regulation of ABCC7 has been widely studied due to its important medical 
impact. All these reasons make the CFTR gene a good example for 
transcriptional studies. The cystic fibrosis (CF), a Mendelian disease, has been 
linked in 1989 to the chloride channel localized in epithelial cells coded by the 
ABCC7 gene (Kerem, Rommens et al. 1989) (Riordan, Rommens et al. 1989) 
(Rommens, Iannuzzi et al. 1989). Since this protein mediates the passive 
transport of small inorganic anions in both directions, the disease is 
characterized by a defect in chloride ion absorption and secretion due to 
mutations in the transporter. To date more than 1000 mutations have been 
described, but it is important to note that up to 90% of cystic fibrosis patients 
have a single mutation (ΔF508) (Lewis, Zhao et al. 2005). The regulation of 
the channel is mediated by phosphorylation/dephosphorylation of serine 
residues by the protein kinase A. The phosphorylation of the regulatory 
domain allows the passage of Cl- (Cheng, Rich et al. 1991) (Csanady, Chan et 
al. 2000). 
Early transcriptional regulation studies have been performed on the ABCC7 
gene after the discovery of its role in CF. First, in silico analysis of a 3.8kb 
region upstream of the transcriptional initiation site revealed that the 
methylation of CpG regions correlates with a low expression level of the gene 
(Koh, Sferra et al. 1993). In parallel, multiple Sp1 and AP-1 binding sites, a 
cAMP response element (CRE), a CCAAT-enhancer binding protein (C/EBP) 
binding site, and several glucocorticoid response elements were identified in 
the promoter sequence by in silico analysis (McCarthy and Harris 2005). The 
promoter of the gene has been analyzed by using promoter deletion 
experiments in order to see specific regulatory region. Thus a minimal 
promoter has been identified between -226 and +98, as well as a negative 
regulatory sequence directly upstream of -227 (Chou, Rozmahel et al. 1991).  
The importance of the cAMP response element, and therefore of cAMP, in the 
basal activity of the promoter was demonstrated by using a specific inhibitor 
of the cAMP-dependent protein kinase A. Using electrophoretic mobility shift 
assay (EMSA), a technique that allows the investigation of protein-DNA 
interaction, McCarthy et al. demonstrated the high binding affinity of CREB 
(cAMP response element binding protein) to the CRE element of the ABCC7 
promoter (McCarthy and Harris 2005). It is interesting to note that at this point 
no regulatory element could explain the tissue specific expression of the gene. 
To identify the potential regulatory elements, different groups used the 
alternative DNase I Hypersensitive Assay technique. This technique allows the 
identification of open chromatin region generally associated with active 
regulatory elements such as enhancers and active promoters in the chromatin 
context by partial digestion with the DNase I enzyme. These sites are called 
hypersensitive sites (Cai, Struk et al.). Thus, using this method, more than 15 
HS related to the ABCC7 gene expression were identified (McCarthy and 
Harris 2005).  
 
Location of the identified HS across the CFTR locus. Map to scale the CFTR gene. Black 
arrows represent HS. Figure has been adapted from Mc Carthy and 2005 
Interestingly only one hypersensitive site located in the first intron of the gene 
exhibits tissue specific properties. Indeed cloning of this sequence in CFTR 
expressing cell line led to an augmentation of the expression of the gene but it 
had no effect in non-expressing ABCC7 cells (Smith, 1996 #64). Further 
analysis of this HS revealed by EMSA that several HNF1alpha transcription 
factors bind to this region and are responsible for the tissue specific expression 
of ABCC7 (Mouchel, Henstra et al. 2004).  
1.5 Pseudoxanthoma elasticum and ABCC6 
Our laboratory has been involved very early in studying the ABCC6 gene and 
the encoded protein, and recently we submitted a review (ABCC6 as a target in 
Pseudoxanthoma Elasticum; András Váradi, Zalán Szabó, Viola Pomozi, 
Hugues de Boussac, Krisztina Fülöp and Tamás Arányi, Current Drug Targets, 
in press) that is a perfect introduction for the MRP6 protein and the ABCC6 
gene. I then used most of it for my introduction on ABCC6. 
1.5.1.1 Pseudoxanthoma elasticum (PXE) 
Pseudoxanthoma elasticum (PXE, OMIM 264800) is a recessive genetic 
disorder with a prevalence of 1 : 25.000 – 100.000, affecting the elastic tissues 
of the body, including the skin, the arteries and the elastic Bruch’s membrane in 
the eye. Patients most commonly present with characteristic papules in the skin 
during late childhood or adolescence and subsequently develop angioid streaks 
of the retina. Angioid streaks are associated with subretinal neovascularisation, 
which can lead to hemorrhage and partial or complete loss of central vision. The 
diagnosis of pseudoxanthoma elasticum is suspected in individuals with 
characteristic skin and ocular findings and is confirmed by histological findings 
on biopsy of lesional skin in which fragmented calcified elastic fibers are 
visualized by use of special histologic stains (e.g. von Kossa staining). 
 
The disease was first described in 1881 by D. Rigal (Rigal 1881) and Félix 
Balzer in 1884, but the term Pseudoxanthoma elasticum (PXE) was first used in 
1896 by Jean-Ferdinand Darier (Darier 1896). In 1889 Robert W. Doyne was the 
first to describe angioid streaks, than Ester Grönblad and James Strandberg 
revealed the connection between PXE and angioid streaks in 1929 (Grönblad 
1929). 
1.5.1.2 The symptoms. 
Cutaneous and mucosal manifestations 
The first sign of PXE is usually yellowish papules on the neck and other flexor 
surfaces. These skin lesions vary in size from 1-5 mm and may be grouped or 
coalesce to form larger plaques. In most of the cases the skin loses its elasticity 
and becomes wrinkled and redundant. In addition to the neck, plaques may also 
appear on other areas, such as axillae, inguinal region, antecubital and polpliteal 
fossae, and periumbilical area during the progression of the disease. In some 
cases mucosal lesions, identical to the skin lesions, can be detected on the inside 
of the lower lip, vagina, and all along the digestive tract mucosal membrane (Hu, 
Plomp et al. 2003). 
The classic histological findings in PXE are ultrastructural elastic tissue 
abnormalities in the middle and lower dermis. In PXE patients elastin becomes 
fragmented and degenerated. Deposition of calcium in the abnormal elastin 
matrix can be visualized by von Kossa or other histological stains for calcium 
(Walker, Frederickson et al. 1989). Similar clinical findings may also be present 
is some other diseases for example in beta-thalassemia (Baccarani-Contri, 
Vincenzi et al. 1994), focal dermal elastosis (Limas 1999), cutis laxa (Choi, 
Kang et al. 2000), calciphylaxis (Nikko, Dunningan et al. 1996) or Paget’s 
disease (Gross 1959).  
However the ultra-structural histopathology is a hallmark of PXE. Even the skin 
findings in a highly related disease (PXE-like disorder with multiple coagulation 
factor deficiency) are in detail slightly different from the skin lesions found in 
PXE patients (Vanakker, Martin et al. 2007). 
Eyes 
Symptoms eventually appear in the eyes in all cases of PXE. The affected areas 
are the Bruch’s membrane and the retinal-pigmented epithelium (Denson, Auld 
et al.). 
In PXE, calcification of dystrophic elastic fibers can be observed in the elastic 
layer of Bruch’s membrane, similar to what is seen in the skin. Pigment 
irregularities, called peau d’orange, may appear in the RPE. Calcification and 
thickening of the Bruch’s membrane, as well as loss of RPE pigment granules 
lead to the development of angioid streaks (AS) (Finger, Charbel Issa et al. 
2009). 
AS are dehiscences in Bruch’s membrane, forming grayish to reddish irregular 
lines resembling vessels, emanating from the optic disk. Due to the calcium 
deposition, Bruch’s membrane becomes fragile, which is thought to be the major 
factor resulting in the dehiscences within the membrane. Later in the course of 
the disease fibrovascular tissue may grow through the damaged membrane, 
leading to choroidal neovascularization (CNV), subretinal fibrosis, atrophy of 
the overlying RPE and retinal hemorrhages (Dreyer and Green 1978). 
Hemorrhages from the fragile new vessels can lead to partial or complete vision 
loss in PXE patients, starting usually around the third or fourth decade of life. 
Central vision loss has the greatest impact on the quality of life in PXE patients, 
but thus far no preventive measures are available. Laser therapy can be used to 
stop the proliferation or the bleeding of submacular neovessels, but it may cause 
visual loss or central scotomas due to scarring, and a high rate of recurrence has 
been observed (Lim, Bressler et al. 1993) (Pece, Avanza et al. 1997). A 
promising therapy to treat ocular symptoms of PXE may be the application of 
antiangiogenic drugs. There have been several publications documenting 
efficacy of intravitreal treatment with vascular endothelial growth factor 
(VEGF) monoclonal antibodies in case of age-related macular degeneration 
resulting in CNVs (Gragoudas, Adamis et al. 2004) (Rosenfeld, Brown et al. 
2006). Similar treatment was already applied for a small group of PXE patients, 
showing very promising results (Finger, Charbel Issa et al. 2008). 
Cardiovascular system 
Calcification may affect the cardiovascular system, mostly the small and middle-
sized arteries. 
Cardiovascular symptoms include diminished peripheral pulses, angina pectoris, 
hypertension, mitral-valve prolapse and restrictive cardiomyopathy (Navarro-
Lopez, Llorian et al. 1980) (Przybojewski, Maritz et al. 1981) (Challenor, 
Conway et al. 1988) (Fukuda, Uno et al. 1992) (Lebwohl, Halperin et al. 1993). 
One of the most common cardiovascular symptoms is intermittent claudication. 
Bleeding, especially gastrointestinal hemorrhages may also occur probably due 
to calcification of the elastic fibers in the small arteries located under the mucosa 
(Fah 1991). Myocardial infarction or other symptoms leading to sudden death 
are rare, but probably the most serious complication associated with PXE is the 
early onset of atherosclerosis (Hu, Plomp et al. 2003).  
ABCC6 as a potential genetic risk factor in Coronary Artery Disease (CAD) 
A strong correlation between a sequence variant of the ABCC6 gene (c.3421C>T 
leading to the p.R1141X non-sense mutation) and CAD has been demonstrated 
in a Dutch cohort (Trip, Smulders et al. 2002). However, a surprisingly high 
frequency of the mutant allele was observed in the control population raising 
doubts about the validity of this unique study on the association of ABCC6 
mutation carrier status and CAD. An independent population genetic study on a 
large Hungarian cohort confirmed the findings of the previous report (Koblos, 
Andrikovics et al.). A significant association of carrier status and CAD was 
observed (5/361 carriers p=0.016 OR=10.5 95%CI 1.22-90.30). These findings 
mean that one non-functioning allele of ABCC6 increases the risk of CAD 
significantly. 
1.5.1.3 PXE like phenotypes. 
The PXE phenotype is highly variable even within a single family where 
patients have the same disease-causing mutations (Hu, Plomp et al. 2003). No 
clear genotype/phenotype correlation has been observed to date (Li, Jiang et al. 
2009). Finally, other diseases can mimic the PXE phenotype. The PXE-like 
syndrome is due to mutations in the gamma-glutamyl carboxylase (GGCX) gene 
(Vanakker, Martin et al. 2007), while certain genetic hemoglobinopathies (e.g. 
thalassemia) lead to slowly developing phenotypes similar to PXE (Hamlin, 
Beck et al. 2003). Although the molecular mechanisms of the developing 
phenotype are not yet understood, in beta thalassemia mice a liver-specific 
down-regulation of Abcc6 gene expression was observed (Edinger 2009). 
Christian Gotting and his co-workers identified a number of genes modifying the 
disease course in a German cohort. They demonstrated that the ABCC6 c.-
219A>C promoter polymorphism is significantly less frequent in patients than in 
the control population (Schulz, Hendig et al. 2006). They also showed that 
certain promoter polymorphism of the SPP1 (secreted phosphoprotein 1, 
previously called: osteopontin) gene were more frequent in PXE patients than in 
controls (Hendig, Arndt et al. 2007). Furthermore, earlier disease onset is 
associated with polymorphisms of catalase, superoxide dismutase and 
glutathione peroxidase genes (Zarbock, Hendig et al. 2007). They also found 
that polymorphisms of the VEGF (vascular endothelial growth factor gene) are 
prognostic markers for ocular symptoms (Zarbock, Hendig et al. 2009). 
Similarly, it was observed that the c.2402C>G p.T801R polymorphism of the 
xylol-transferase II genes is associated with increased PXE severity (Schon, 
Schulz et al. 2006).  
1.5.2 The ABCC6/MRP6 protein. 
The domain architecture of the ABCC6/MRP6 shares the general features of the 
ABC-kingdom and is formed of the following domains: TMD0-L0-TMD1-
ABC1-L1-TMD2-ABC2 (L0 and L1 are intracellular loop). ABCC6 consists of 
1503 amino acids and it is known that the protein functions as an organic anion 
transporter (Ilias, Urban et al. 2002) (Belinsky, Chen et al. 2002). Indeed, in 
vitro studies demonstrated the transport of glutathione-conjugates like 
glutathione S-conjugated leukotriene C4 (LTC4), N-ethylmaleimide S-
glutathione (NEM-GS) and S-(2,4-dinitrophenyl) glutathione, while the rat 
orthologue transports an anionic cyclopentapeptide (Madon, Hagenbuch et al. 
2000). It has also been shown by in vitro assays that some missense mutations 
described as causative mutations in pseudoxanthoma elasticum result in the loss 
of ATP-dependent transport of test substrates (Ilias, Urban et al. 2002). 
Compared with its sub-family members (ABCC1-5) ABCC6 is a poorly 
characterized transporter. The protein shows significantly lower transport rate 
(turnover number) than the other human ABCC-type transporters, which makes 
its detailed biochemical/functional characterization difficult.  
It has been suggested that overexpression of ABCC6 is able to confer low 
levels of resistance to several commonly used natural product anticancer 
agents like etoposide, doxorubicin, daunorubicin and actinomycin D 
(Belinsky, Chen et al. 2002). However, clinically relevant ABCC6-mediated 
drug resistance has never been found. 
1.5.2.1 Homology models 
No high-resolution three-dimensional structure of ABCC6 is available. 
However, a three dimensional homology model of ABCC6 is already published 
(Fulop, Barna et al. 2009), made possible by the recent publication of high 
resolution crystalline structures of ABC proteins (Dawson and Locher 2007) 
(Aller, Yu et al. 2009) (Dawson and Locher 2006).  The structures representing 
the nucleotide-saturated, outward facing conformation show that the two 
nucleotide-binding (ABC) domains are in close proximity to each other in the 
characteristic head-to-tail orientation reflecting to the previously described 
"nucleotide sandwich dimer" (Smith, Karpowich et al. 2002).  Newly recognized 
structural elements are the long "rigid" extensions of the transmembrane helices, 
called intracellular loops (ICL). Each half of the ABC proteins has two ICLs 
interacting with the ABC-domains. The coupling helices contact with their 
“own” as well as with the “opposite” ABC-domains, hence a special type of 
domain swapping can be recognized in the structure.  
We have constructed two homology models of human ABCC6 protein: one of 
the models is based on the Sav1866 bacterial ABC transporter structure (Fulop, 
Barna et al. 2009) representing a nucleotide-saturated conformational state, 
while the other one uses the recently published mouse Abcb1 structure as 
template and represents the nucleotide-free (apo) conformation (Váradi et al, 
unpublished). By performing a statistical analysis we have found a significant 
clustering of the missense PXE-mutations at the domain-domain interfaces: at 
the transmission interface that involves four intracellular loops (ICLs) and the 
two ABC domains as well as at the ABC - ABC interacting surfaces. In the 
nucleotide-saturated model the mutations affecting these regions are 2.75 and 
3.53 fold more frequent than the average mutational rate along the protein 
sequence, respectively (Fulop, Barna et al. 2009). At the predicted ICL-ABC 
interfaces in the nucleotide-free model the mutational rate is 4.25-fold more 
frequent than the average mutational rate along the protein sequence (the ABC 
domains are distant in this conformation) (Váradi et al, unpublished). The 
observed significant clustering means that the domain contacts are much less 
permissive to amino acid replacements than the rest of the protein. These results 
provide a “bridge” between genetic data and protein structure and can be viewed 
as novel proof of the importance of the studied domain-domain interactions in 
the ABCC6 transporter.  
1.5.3 Animal models 
Abcc6 knock out mouse models were generated and the critical role of Abcc6 in 
ectopic mineralization/calcification has been confirmed in the Abcc6-/- mice, 
which recapitulates the genetic, histopathologic and ultrastructural features of 
PXE (Klement, Matsuzaki et al. 2005) (Gorgels, Hu et al. 2005). These findings 
suggest that the function of this transporter is conserved in the mouse. 
Calcification in the vibrissae capsules is the first symptom of the calcification 
phenotype detected at the 8 to 10 weeks of age and serves as an early biological 
marker of the disease (Klement, Matsuzaki et al. 2005). A slight alteration of 
plasma lipid composition of the Abcc6-/- mice has also been reported (Gorgels, 
Hu et al. 2005). The KO mouse models have been utilized for physiological and 
for pharmacological studies that are discussed elsewhere in this paper. 
Dystrophic Cardiac Calcification (DCC) in the mouse is an autosomal recessive 
trait in certain laboratory strains and the Abcc6 gene locus has been recently 
found as a main mediator of DCC at the Dyscalc1 locus (Meng, Vera et al. 
2007) (Aherrahrou, Doehring et al. 2008). A splicing error in processing of 
Abcc6 mRNA has been identified as the causative genetic event (“splice-
mutation”) of DCC. This mouse shows a more pronounced arterial calcification 
phenotype than the one observed in the laboratory-generated Abcc6-/- mice 
strains (presumably due to the different genetic background) and seems to be as 
good model of PXE as the latter. 
The zebrafish (Danio rerio) has nearly the same ABC gene repertoire as the 
human and has an accessible and well-characterized embryo. Two morpholinos 
were designed targeting two different regions of the Abcc6a gene (the ABCC6b 
gene was found to be inactive), and it was observed that they decrease Abcc6a 
expression by 54 and 81%. Both morpholinos induced a similar phenotype, 
cardiac edema and curled tail. Microinjecting zebrafish larvae with full-length 
mouse Abcc6 mRNA completely rescued the knockdown phenotype (Qiaoli Li 
2010). These recent results serve as basis of a novel knockdown animal model 
system. However, the results provided by this model may not be translated 
directly to human physiology, as the zebrafish gene appears to be essential for 
the development of the animal. 
1.5.4 The ABCC6 gene 
In 2000 it was discovered by positional cloning that mutations in ABCC6 gene 
are responsible for the development of PXE (Le Saux, Urban et al. 2000) 
(Bergen, Plomp et al. 2000) (Ringpfeil, Lebwohl et al. 2000). Since the 
discovery of the connection between ABCC6 mutations and PXE a large number 
of disease-causing mutations has been identified; the most frequent ones are 
p.R1141X (20 – 30%) and c.EX23_29del (5 – 15%). The high heterogeneity of 
PXE alleles in the population is comparable to that of other autosomal diseases. 
A locus-specific database has been established recently with the collection of the 
disease-causing mutations and other genetic variants and with link to other 
genetic databases [www.ncbi.nlm.nih.gov/lovd/home.php?select_db=ABCC6]. 
ABCC6 is located at 16p13.11 and codes for the ATP-binding cassette 
transporter protein, ABCC6/MRP6. The functional gene of 75 kb size consists of 
31 exons. Two pseudogenes that are expressed at low levels and are positioned 
centromeric (ABCC6-ψ1) and telomeric (ABCC6- ψ2) of ABCC6 have also been 
mapped (Pulkkinen, Nakano et al. 2001). Both ABCC6-ψ1 and ABCC6-ψ2 share 
a high degree of sequence similarity (~99%) with the functional gene, but are 
truncated in the fourth and ninth intron, respectively. The ABCC6 locus is 
located in a genomic region that was subject to segmental duplications, a series 
of events thought to play a crucial role in the recent evolution of ABCC6 gene 
cluster (Symmons, Varadi et al. 2008). Due to this evolutionary scenario 
chromosomal rearrangements, gene conversion and emergence of new genes 
have been observed. 
There are several reports indicating that the ABCC6 locus is genetically unstable. 
A rare fragile site (FRA16A) has been found in close centromeric proximity to 
ABCC6 (Cai, Struk et al. 2000), while the breakpoint of rearranged Chromosome 
16 in the acute non-lymphocytic leukemia cell line M4Eo was localized ~0.5 Mb 
telomeric of ABCC6 (Dauwerse, Wessels et al. 1993) (van Dongen, Macintyre et 
al. 1999). ABCC1, the gene located closest to ABCC6 (8 kb apart) is frequently 
deleted in the drug-selected M4Eo cell line, and the concomitant amplification 
of ABCC1 and ABCC6 is observed in the SKOV3 ovarian carcinoma cell lines 
after multidrug selection (Buys, Chari et al. 2007). 
1.5.5 Transcriptional regulation 
The initial characterization of the transcriptional regulation of the human 
ABCC6 gene identified two evolutionarily conserved regions in the 5’ sequence 
10kb upstream from the translation start site (Aranyi, Ratajewski et al. 2005). 
Both regions harbor a CpG island (CGI), potential target of DNA methylation. 
Analysis of DNA methylation may give clues to the location of important 
regulatory regions of gene expression, as methylation is stable like an imprint. 
Methylated regions indicate silenced and unmethylated regions design 
transcriptionally active sequences (Aranyi, Faucheux et al. 2005). Bisulfite 
genomic sequencing was carried out to analyze both the distal and the proximal 
CGI in different cell lines expressing and non-expressing ABCC6 (Aranyi, 
Ratajewski et al. 2005). Cell-type specific DNA methylation in the proximal 
CpG island was detected, which inversely correlated with the expression of the 
gene and suggested that this region plays an important role in the tissue-specific 
regulation of ABCC6. 
Based on these data luciferase reporter gene assays were performed with 
sequential deletion promoter constructs. One silencer (between -713 and -332 
bp) and one DNA methylation sensitive activator sequence (between -332 and -
145 bp) were identified. These data indicated that this region confers tissue-
specificity to the ABCC6 expression pattern. Further promoter mapping 
experiments confirmed these findings by identifying one tissue-specific 
regulator element (between -209 and -145 bp) and one further stronger activator 
sequence located between -234 and -209 bp (Ratajewski, Van de Ven et al. 
2008).  
The potential regulatory role of some transcription factors and cytokines has 
been suggested. The binding of the PLAG family of transcription factors and 
RXR has been convincingly demonstrated: they are able to transactivate the 
endogenous ABCC6 gene, the binding site was determined by luciferase assay 
and the binding to the ABCC6 promoter in the natural chromatin environment 
was demonstrated by chromatin immune precipitation. However, their functional 
role is still unclear (Ratajewski, Bartosz et al. 2006) (Ratajewski, Van de Ven et 
al. 2008). The binding of NF-κB, SP1 and TGF-β has been also suggested but 
their functional role and their binding to the endogenous ABCC6 promoter have 
not been tested (Jiang, Matsuzaki et al. 2006). 
Signal transduction pathways leading to the modulation of ABCC6 expression 
have also been deciphered. Initially the activation by TGF-β and inhibition by 
TNF-α and IFN-γ were reported in luciferase reporter gene assays (Jiang, 
Matsuzaki et al. 2006). However, these effects have not yet been confirmed on 
the endogenous gene and the implicated signal transduction pathway was not 
identified.  
1.5.6 The PXE-like syndrome 
ABCC6 is predominantly expressed in the liver in the basolateral compartment 
of the plasma membrane of the hepatocyte (and to a lesser extent in the kidney), 
while the symptoms are systemic affecting various organs. This apparent 
discrepancy led to the hypothesis that PXE is a metabolic disease suggesting that 
ABCC6 is involved in secretion of a metabolite from the liver into the 
circulation (Uitto, Pulkkinen et al. 2001). Recent experiments demonstrated that 
grafting of wt mouse muzzle skin onto the back of KO mice triggered 
mineralization, whereas grafting KO mouse muzzle skin onto wt mice was 
accompanied with no mineralization (Jiang, Endo et al. 2009). These 
transplantation experiments argue that PXE is indeed a metabolic disorder. 
Furthermore, in a parabiotic experiment the surgical pairing of Abcc6(-/-) mice 
with wild-type prevented the mineralization of the connective tissue in the 
knockout mice (Jiang, Oldenburg et al.). 
There have been a few case reports of a disease that phenotypically resembled 
pseudoxanthoma elasticum with respect to the mineralization of soft tissues 
causing cardiovascular, dermal and ocular symptoms. However, these patients 
suffer from a vitamin K-dependent coagulation factor deficiency which is not 
seen in PXE (Macmillan and Vickers 1971) (Rongioletti, Bertamino et al. 1989) 
(Le Corvaisier-Pieto, Joly et al. 1996). The disorder is extremely rare and for 
decades its molecular basis remained unknown. Also, no mutations in the 
ABCC6 gene could be detected in these individuals, suggesting that mutation of 
another gene could also cause PXE-like soft tissue calcification. The identity of 
this enigmatic gene was unraveled recently (Vanakker, Martin et al. 2007), and 
the clinical condition was classified as a novel disorder: PXE-like disease 
(pseudoxanthoma elasticum-like disorder with multiple coagulation factor 
deficiency, OMIM 610842). Six patients were found to possess compound 
heterozygous mutations in the gamma-glutamyl carboxylase (GGCX) gene. 
The GGCX gene encodes the gamma-glutamyl carboxylase enzyme (GGCX), an 
ER (endoplasmic reticulum)-resident protein, responsible for post-synthetic 
carboxylation of Gla-domain containing proteins to which they confer Ca-
binding properties (Berkner 2008). During the carboxylation reaction, vitamin K 
(VitK) is oxidized to an epoxide form, which is then re-reduced by another 
enzyme, Vitamin K oxido-reductase (VKORC1), thereby completing the VitK-
cycle (Oldenburg, Marinova et al. 2008). 
The highly similar phenotypic features of the two diseases evoked hypotheses 
about their overlapping patho-physiology.  In PXE-like disease – due to the 
mutations of the GGCX enzyme - the Gla-gammacarboxylation is reduced in the 
liver, thus resulting in blood coagulation abnormality, and also in the 
extrahepatic soft tissues where the control of calcification is impaired. In 
classical PXE gamma carboxylation is normal in the liver as there is no mutation 
in GGCX. According to the current hypothesis, in extrahepatic tissues gamma 
carboxylation is lower than normal as Vitamin K available for the carboxylation 
cycle may be limited in those tissues.  
These data raises the possibility that one form of Vitamin K is transported from 
the liver into the circulation, and this transport is mediated by ABCC6 (and is 
missing in PXE due to ABCC6 mutations) (Borst, van de Wetering et al. 2008). 
On the other hand, the fact that PXE is a slowly progressive disease suggests 
that the metabolite transported by ABCC6 may only be reduced but not 
completely absent in the circulation of patients.  
However, the key role of Vitamin K in the disease phenotypes associated with 
ABCC6 has not been proven. 
Finally the local expression of ABCC6 has been shown in several tissues and 
cell types, e.g. keratinocytes, fibroblasts, smooth muscle cells and macrophages 
(Hendig, Langmann et al. 2008) (Beck, Hayashi et al. 2005) (Boraldi, Quaglino 
et al. 2003), some of those are affected in PXE. The local effect of missing 
ABCC6 activity may also contribute to the progression of the disease.  
1.5.7 ABCC6 as a drug target 
Two disease conditions are associated with mutations in the ABCC6 gene: 
pseudoxanthoma elasticum is a recessive trait due to mutations in both ABCC6 
alleles, while the loss of one functional ABCC6 allele is a genetic risk factor in 
coronary artery disease, CAD. As the phenotype in both cases is due to complete 
or partial loss of ABCC6 activity, augmentation-type gene therapy – in principle 
– could be an effective treatment of the disease conditions. However, even if all 
the safety concerns of gene therapy were solved, there are questions to be 
answered: is it sufficient to restore ABCC6 activity only in the liver, or it is also 
needed to do in other organs with lower level of expression (e.g. kidney)? 
Missense disease-causing mutations can reduce the transport activity and/or the 
overall stability of the transporter, or may result in a slightly altered 
conformation that is not compatible with the normal trafficking of the protein to 
the plasma membrane. Indeed, defective protein trafficking caused by mutations 
underlies many human diseases and examples include several membrane-
embedded ABC-proteins (like ABCC7/CFTR, ABCC2, ABCC8/SUR1 or 
ABCB11/BSEP). Efforts to identify pharmacologic compounds to correct the 
misfolding and/or misprocessing of mutant membrane proteins have already 
resulted in a few remarkable findings, and are considered as the molecular basis 
of allele-specific therapy of the given disease (Hayashi and Sugiyama 2007). 
This observation raises the possibility that pharmacological compounds (acting 
either as “chemical chaperones” or interfering with the quality control of the 
protein sorting/processing mechanism) may correct the defect causing the 
disease in a group of patients.  Substrates and modulators of ABCB1 have been 
demonstrated to act as chemical chaperones thus helping the appearance of fully 
mature protein at the cell surface in the case of processing ABCB1 mutants (Loo 
and Clarke 1997). The first effort of promising correcting of folding of the 
delta508CFTR mutant was achieved by curcumin, which might act as a chemical 
chaperone (Egan, Pearson et al. 2004). High-throughput screening systems can 
be designed to test large chemical libraries for other “corrector” compounds. We 
have constructed a Hemagglutinin (HA) epitop-tagged version of human 
ABCC6: the antibody-reactive tag has been inserted into the extracellular N-
terminal segment of the protein (Iliás and Váradi, unpublished). The protein 
preserved transport activity and showed cell surface expression similar to the 
wild type, and the HA tag recognized on the surface of intact, ABCC6-
overexpressing cells provided a signal for correct trafficking. However, such an 
approach has inherent limitations in the case of ABCC6. In PXE – in contrast to 
cystic fibrosis, where deltaF508CFTR mutation is present in the majority of the 
patients – there is no such a high frequency mutation.  It is expected, that 
different traffic-defect mutants are arrested at different points of the trafficking 
pathway and may need different “intervention”.  
The most frequent mutation in PXE is the p.R1141X nonsense mutation. It has 
been shown that aminoglycoside antibiotics like gentamicin can suppress 
premature stop codon arrest of translation by inducing the ribosome to read 
through (or “suppress”) the nonsense mutation via insertion of a random amino 
acid. It was demonstrated in a muscular dystrophy mouse model that 
aminoglycosides could suppress stop codons not only in vitro but also in vivo 
(Barton-Davis, Cordier et al. 1999). However, the efficacy of the “read through” 
may be quite low. Enhanced production of active protein from genes with 
nonsense mutations can be achieved by combining treatment by inducing the 
promoter of the gene and the application of “read through” agents (Xi, Guan et 
al. 2004). These strategies can now be tested in experiments with the aim of 
correcting the frequent ABCC6 p.R1141X stop codon mutation. 
2  Objectives 
1) We aimed to find physiological pathway regulating ABCC6 expression. In 
that purpose we looked for different molecules that can increase or decrease 
the ABCC6 expression. Those can be either drugs or transcription factor 
agonists. Our strategy was to perform a screening on the liver HepG2 cell line, 
and to follow ABCC6 expression variation by quantitative RT-PCR.  
2) We aimed to map the different potential regulatory regions of the ABCC6 
gene. We used the DNAse I digestion technique to identify sequences with 
transcriptional regulatory abilities in the endogenous chromatin environment. 
This technique is used in a hypothesis free context, which is a major advantage 
since hypothesis could lead to over or underestimation of the importance of 
specific sequences. This experiment was done on different cell lines to detect 
possible cell specific regulation profiles. Regulatory regions found by DNase I 
assay were then analyzed by luciferase assay and by bioinformatic tools to 
identify the factors potentially involved in the regulation of the gene. 
That study contributes to a better understanding of the ABCC6 transcriptional 
regulation, and we believe that it will give a better understanding of the 
disease linked to ABCC6 mutations. 
 
Before starting I need to emphasize that I carried out this project in tight 
collaboration with Lukasz Pulaski’s group in Poland (Laboratory of 
Transcriptional Regulation, Institute of Medical Biology). The luciferase 
experiments that are part of my results were carried out in Lodz (Poland) 
together with or by Marcin Ratajewski. In the frame of the collaboration I 
went there three times to perform experiments. Moreover, the design of the 
constructs and of the luciferase experiments were completed following intense 
discussions between the Polish group and us. Of the sixteen new designed 
constructs used in that work, seven were cloned in Lodz, and nine were cloned 
in Budapest. 
 
Objectives representation, and the different strategies used. Thin arrows indicate the influx of 
information used to study the transcriptional regulation of ABCC6 gene. Thick arrows 
indicate the results leading to the understanding of transcriptional regulation of ABCC6 
gene. 
3  Material and methods 
3.1 Cell culture and treatments  
HepG2 human hepatoma cell line was obtained from ATCC, and cultured 
according to the manufacturer’s instructions in Minimum Essential Media 
(MEM (Advanced)) (invitrogen) in a humidified atmosphere of 5%CO2/95% 
air. The medium was supplemented with 10% Fetal Bovine Serum (Gibco), 
2mM glutamine, and 100 U/ml penicillin and 100ug/ml streptomycin. Caco2 
cells were obtained from ATCC and cultured in the same condition than the 
HepG2, except that the media was supplemented with 20%FBS. HeLa and 
HEK293 cells were cultured in RPMI supplemented with 10% FBS, 2mM 
glutamine, and 100 U/ml penicillin and 100ug/ml streptomycin. 
For HepG2 treatments, cells were maintained in 24 wells plate, and 
approximately 1*105 cells were seeded per well. Treatments were performed 
24hours after seeding the cells, and the RNA was extracted 24hours after 
treatment. Before treatment, cells were cultured in medium without serum, and 
in the case of co-treatment the different inhibitors were added 1hour before 
addition of the activators.  
The different molecules have been used at the following concentration: 
(Sigma-Aldrich): hepatocyte growth factor (HGF, human, recombinant) 
40ng/ml, epidermal growth factor (EGF) 100ng/ml, insulin 5ug/ml, TGFbeta 
5ng/ml, phorbol myristate acetate (PMA) 100nM, menadione 5uM, tert-butyl 
hydroquinone (tBHQ) 75nM, (Calbiochem, San Diego, CA): U0126 2uM, 
bisindolylmaleimide I BIMI 500nM, LY294002 20uM. 
3.2 DNase I hypersensitive assay 
6.106 Cells were collected and resuspended in 100 µl of Ψ buffer (11 mM 
KPO4 pH 7.4; 108 mM KCl;  22 mM NaCl; 1 mM MgCl2; 1 mM DTT; 1 mM 
ATP) at (4°C), and were then treated by Dnase I during 3minutes on ice with a 
concentration range of DNase I. The DNase I digestion was stopped by the 
addition of 2.5ml of lysis buffer (50 mM Tris-HCl pH 8; 20 mM EDTA; 1% 
SDS). 
3.3 Genomic DNA extraction 
The Genomic DNA was extracted by phenol and ethanol precipitation, gDNA 
was resuspended in TE and quantified by optical density at 260nm. 
3.4 Southern blot 
Twenty micrograms of DNase I-treated gDNA was digested overnight by the 
selected restriction enzyme then gel electrophoresis was performed overnight 
at 24V on a 1% TAE gel. The DNA was transferred to a nylon membrane and 
fixed by UV during 10minutes. Selected probe (P61 or P62) was labeled with 
32P-dCTP using the DecaLabel™ DNA Labeling Kit (Fermentas). Membrane 
was incubated in hybridization solution (QuickHyb, Stratagene) 30minutes at 
65°C. Then the labeled probe was added at a concentration of 
1.25*106cpm/ml, with 100ul herring sperm DNA previously sonicated to 
obtain fragment form 500bp to 1kb, and incubated 3h at 65°C. Membrane was 
then washed with 1X SSC washing buffer 5ml SSC 20X + 90 ml dW + 5ml 
SDS 10% for 10min at 37°C. Following washings were performed with more 
stringent condition by decreasing the concentration of SSC in the washing 
buffer. Thus next washing buffer contained 0.2X SSC etc… Membrane was 
washed until radioactivity measured on it decreases to 5 cpm/s. Membrane 
was exposed to hyperfilm (Hammersham) for 24-36h at -80°C. The DNase I 
hypersensitive sites were visualized by submitting the film to Developer and 
manual fixing bath solution (AGFA) 
3.5 RNA extraction 
Cells were resuspended in TRI REAGENT (Molecular Research Center, Inc.). 
Total RNA was extracted and purified by phenol chloroform and isopropanol 
precipitation. The concentration of extracted RNA was measured at 260 nm. 
3.6 cDNA synthesis, reverse transcription. 
A 20µl reaction mixture containing 500ng of total RNA was reverse-
transcribed to cDNA using the High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems). 
3.7 Real time PCR 
One microliter of synthesized cDNA served as template in a 10ul reaction, 
qPCR was performed with LightCycler FastStart DNA Master SYBR Green I 
(Roche) in an LC480 quantitative PCR machine (Roche). qPCR was 
performed at 95°C for 10min, followed by 40 cycles with denaturation at 95°C 
for 10s, annealing at 60°C for 5s, and extension at 72°C for 20s, fluorescence 
detection was performed at 87°C for 5s for the ABCC6 gene, and at 80°C for 
5s for the other genes. Denaturation curves of PCR products were determined 
by increasing temperature at the rate of 0.1/min from 55 to 95°C. Fluorescence 
of samples was continuously traced during this period. All the melting curves 
of PCR products gave a single peak. Agarose gel electrophoresis of 
representative reactions was used to confirm amplification of unique fragments 
of predicted lengths. All the results are expressed as the means ± S.E. of four 
independent experiments. The expression of target gene was normalized to the 
ABL gene used as an internal control according to the 2−ΔCt formula.  
Primer sequences are the following: ABCC6 forward 
GGCCCGGGCATCCAGGTT, and reverse 
TTTCATCTACGCGAGCATTGTTCT, URG7 forward 
TACCTCCTCTTCATCCACCACCAT, and reverse 
CCCTGCCTCCCCCGAACATTG, ABL forward 
GGGCTCATCACCACGCTCCA, and reverse 
CTGCCGGTTGCACTCCCTCA. 
3.8 Cloning 
Reporter plasmid vectors containing the ABCC6-PXE promoter sequences 
were constructed by PCR cloning. Human genomic DNA was used as 
template for amplification of the longest construct -332/+960, then this 
construct was used as template for the amplification of the other one. The -
718/+72, -332/+72, -145/+72 reporter constructs were described previously 
(Aranyi, Ratajewski et al. 2005). 
The following sequence specific primers were designed using the Bisearch 
software. Forward primer: -332 TCGGTACCGATTCTTGTTGCAGGGGG; -
234 CTCGGTACCCGCCTCTCTTCCCCCAT; -209 
CCGGTACCTCGCCTGTTTTCACCTCC ; -145 








CAAAAGCTTTCAAGCAATCCTCCCACC. The restriction sites (KpnI site 
for forward primers and HindIII site for reverse primers) were added to the 5′-
end of primers, and promoter sequences were amplified using high fidelity 
thermostable DNA polymerase (TaqPfu). PCR products were cloned into the 
pGL3-Basic vector (Promega) to construct the following plasmids 
phABCC6(–332/+513)Luc, phABCC6(–332/+629)Luc, phABCC6(–
332/+652)Luc, phABCC6(–332/+688)Luc, phABCC6(–332/+716)Luc, 
phABCC6(–332/+817)Luc, phABCC6(–332/+960)Luc, phABCC6(–
145/+629)Luc, phABCC6(–145/+652)Luc, phABCC6(–145/+688)Luc, 
phABCC6(+72/+629)Luc, phABCC6(+72/+652)Luc, 
phABCC6(+72/+688)Luc, phABCC6(–234/+688)Luc, phABCC6(–
209/+688)Luc, phABCC6(+479/+960)Luc. The sequence of the cloned inserts 
was tested for the amplification of the ABCC6-PXE gene and the lack of errors 
by automated sequencing. 
3.9 Luciferase assay 
Ten thousands cells were seeded per well in a 96 well plate. After 24h, the 
plasmids were transfected by polyethyleneimine transfection reagent 
(Exgen500, Fermentas). Cells were harvested and lysed 48h after transfection. 
The activity of luciferase in cell lysate was determined in an EnVision 
luminometric plate reader (Perkin Elmer) using a commercial luciferase 
substrate (BD Biosciences). All cells were also transfected with a pCMV-
SEAP reporter vector encoding secreted alkaline phosphatase under the 
control of a constitutive cytomegalovirus-derived promoter (kind gift from Dr. 
S. Schlatter, Zurich) as an internal control for transfection efficiency. The 
level of alkaline phosphatase activity was determined spectrophotometrically. 
The luciferase assay treatments were carried out at the indicated concentration 
24hours after transfection and for 24hours. Co-transfections of reporter 
constructs and plasmids carrying cDNA for selected transcriptional factors 
were performed analogously to normal transfection. Expression plasmids were 
bought from Origene Technologies Inc. (Rockville, USA).  
3.10 Western blot 
Whole cells were cultured and treated with selected compounds on a 6 well 
plate and were lysated using 0.5ml of the following buffer 30mM HEPES, 
10mM NaCl, 5mM NaF, 1mM EGTA, 1% triton X-100, 10mM benzamindine, 
1mM Na3VO4, 20ug/ml leupeptin, 1mM Phenylmethylsulphonyl fluoride. 
Lysates were harvested and clarified by centrifugation at 15 000g for 10 
minutes at 4°C. Protein content was determined with the Lowry assay, and 
equal amount of protein was subjected to SDS-PAGE using 7.5%running gels. 
Proteins were transferred to nitrocellulose filters and membranes were blocked 
with 5% dry milk in TBS-Tween (TBS containing 0.05% Tween 20) overnight 
at room temperature. Then membranes were incubated for 120minutes with 
the selected primary antibody (antibodies against ERK1/2, or phospho-
ERK1/2 (Thr202/Tyr204) purchased from Santa Cruz, CA. respectively K-23 
and E-4) at room temperature. Membranes were then washed and incubated 
60minutes with a species-specific horseradish peroxidase-labeled secondary 
antibody at room temperature (anti-mouse for the anti-ERK-P (E-4), anti-
rabbit for the anti-ERK (K-23)). Protein-antibody interaction was detected by 
using the enhanced chemiluminescence technique (ECL, Amersham 
Biosciences). The quantitative measure of expression level was determined by 
densitometry of the immunoblots.  
3.11 Bioinformatic 
For the in silico sequence analysis the following web servers were used: P-
Match; Matinspector; TF-search. 
3.12 Statistical analysis 
Statistical analysis was performed using Student’s t-test to compare the two 
groups and ANOVA was used for multiple comparisons when the three groups 
or more were compared. P < 0.05 was considered statistically significant. The 
results were expressed as mean ± SE. Values were analyzed using the 
statistical software Instat. 
4  Results 
4.1 ABCC6 is regulated by a physiological pathway 
4.1.1 Identification of drug compounds modulating ABCC6 
expression 
The transcriptional regulation of the ABCC6 gene has already been 
investigated. The promoter was characterized and regulatory elements of the 
promoter were highlighted, with an activator located between -332 and -145bp 
from the translational initiation site of the gene, and an inhibitor located 
5’upstream -332 (Aranyi, Ratajewski et al. 2005). Additionally the Sp1, RXR 
and PLAG transcription factors were shown to play a role in its regulation 
(Jiang, Matsuzaki et al. 2006) (Ratajewski, Bartosz et al. 2006) (Ratajewski, 
Van de Ven et al. 2008). The chromatin context of the gene was also 
investigated by DNA methylation analysis of the promoter and tissue specific 
pattern correlation with the expression of the gene was detected in human and 
mice as well (Aranyi, Ratajewski et al. 2005) (Douet, Heller et al. 2007). But 
to date no physiological relevant physiological pathways regulating the 
expression of ABCC6 were determined, and we therefore decided to 
investigate this issue. 
ABCC6 is mainly expressed in the liver, for that reason we chose the most 
relevant hepatocellular carcinoma cell line. The HepG2 cell line is highly used 
in the literature as a liver model and was selected for its ability to express 
ABCC6 at high level. 
I will use in that thesis the word “drug”, as transcriptional regulation studies 
do, for the different compounds used to modulate the expression of the 
ABCC6 gene. We performed the drug screening on the HepG2 cell line, 
choosing the drugs for their ability to regulate numbers of various pathways.  I 
am going to detail only the drugs that turned out to be the most relevant ones 
(Table 1).  
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Table 1. ABCC6 expression is inhibited by various drugs. HepG2 cells were treated with the 
indicated compounds (HGF, Butyrate, Oltipraz, TCDD, BNF, tBHQ) or vehicle for controls 
(DMSO) in serum free conditions for 24 hours. Relative ABCC6 expression level was 
determined by quantitative PCR after normalization to the ABL housekeeping gene expression 
level as described in the methods. Expression levels are indicated as a percent of untreated 
control. Four parallels were used for each condition. The experiments were repeated three 
times, *p<0.05. 
After the drug screening we filed the different agonist or inducers tested in 
two different groups. Most of the drugs showed inhibitory effect on the 
ABCC6 gene expression, and others do not exhibit any effect (table 1).  
4.1.2 Growth factors down-regulate the expression of ABCC6. 
The transmission of signals from the cell membrane to their intracellular 
targets is dependent of a complex network of proteins present in the 
cytoplasm. That network transmits the signal via a number of interactions, and 
inter-activation processes. The kinase cascades are among these signal 
transmission processes (Seger and Krebs 1995). Thus, following the binding 
of HGF on the hepatic cell membrane, three major kinases are activated: the 
PI-3k, involved in glucose regulation, the PKC and the MAPK. The complex 
regulation processes following the activation of these cascades lead to the 
activation and inhibition of a set of different genes in order to complete 
specific actions. In the case of the MAPK activation the cell growth and 
differentiation are privileged while for the PI-3k the response to insulin is 
advantaged.  
Interestingly in the case of treatment with the HGF and EGF we observed 
similar inhibition of the ABCC6 expression, indicating a possible important 
role of the growth factors in ABCC6 regulation, while treatment with 
TGFbeta, another important growth factor, did not result in a significant 
inhibition of ABCC6 expression (Figure 1).  
It is well known that the activation of the c-Met membrane receptor by its 
ligand HGF leads to the activation of three major cellular cascades in the cell 
which are the PI-3k, the PKC and the MEK1/2 cascades (Figure 2). We 
decided to investigate in more details this interesting finding. 
 
 
Figure 1. Effect of growth factors on ABCC6 gene expression. HepG2 cells were treated with 
HGF, EGF and TGFbeta or vehicle for controls (DMSO) in serum free conditions for 
24hours. Relative ABCC6 expression level was determined by quantitative PCR after 
normalization to the ABL housekeeping gene expression level as described in the methods. 
Expression levels are indicated as a percent of untreated control. Four parallels were used for 
each condition. The experiments were repeated three times, mean±SE *p<0.05. 
To understand the molecular mechanism of the regulation of ABCC6 by HGF 
we decided to screen the pathways one after another. In that purpose, we used 
different specific inhibitors of the kinases: LY294002; BIMI and U0126 
respectively for the PI-3k, the PKC and the MEK1/2 cascades.  
 
Figure 2. HGF leads to the activation of various pathways in cells. 
The concentration of the molecules used for the treatments were chosen 
according to the literature as the HepG2 hepatic model cell line is a widely 
used cell line. It is known that the Fetal Bovine Serum usually used in cell 
culture contains various growth factors. Those factors can activate the kinase 
cascades we aimed to investigate. Therefore to avoid any uncontrolled 
activation by the factors contained in the serum, we maintained the cells in 
serum free medium. Before treatment and one hour before adding the different 
kinase agonists, cells were treated with the specific inhibitors (Figure 2).  
First of all we considered the possible involvement of the PI-3k on the ABCC6 
expression regulation. Insulin is known to be an activator of the PI-3k cascade, 
but treatment with insulin did not show any inhibitory effect on the expression 
of ABCC6. However, we also performed co-treatment of HepG2 cells with the 
PI-3k specific inhibitor LY294002 and HGF to confirm the results observed 
with insulin (Figure 3). LY294002 treatment did not prevent the inhibition of 
ABCC6 expression by HGF showing that the PI-3k pathway is not involved in 
the expression regulation of ABCC6.  
 
Figure 3. PI-3kinase pathway does not modulate ABCC6 expression. HepG2 cells were 
treated with HGF or LY294002 (indicated as LY on the figure), a specific inhibitor of PI-3K 
or in combination or vehicle for controls (DMSO) in serum free conditions for 24 hours. 
When co-treatment was applied LY294002 was added to the cells 1 hour before HGF Relative 
ABCC6 expression level was determined by quantitative PCR after normalization to the ABL 
housekeeping gene expression level as described in the methods. Expression levels are 
indicated as a percent of untreated control. Four parallels were used for each condition. The 
experiments were repeated three times, mean±SE *p<0.05 
Next, we analyzed the PKC pathway, and in that purpose, we performed PMA 
treatment, a specific PKC activator, on HepG2 cells. As already described we 
first observed a phenotypic change of the HepG2 cells after 24hours treatment 
(Sipeki, Bander et al. 1999) (Gujdar, Sipeki et al. 2003), showing that the 
treatment was efficient. The following analysis of the ABCC6 gene expression 
showed an inhibition of almost 70% of the expression of the gene, 
highlighting a possible role of PKC on the regulation of ABCC6 gene 
expression. To further investigate the role of PKC, we performed co-treatment 
of PMA and BIMI a specific inhibitor of the PKC activation. Surprisingly 
BIMI did not prevent the inhibition of ABCC6 expression by PMA (Figure 4).  
 
Figure 4. Atypical PKC subfamily member(s) inhibit the expression of ABCC6. HepG2 cells 
were treated with PMA or HGF or BIM, a selective inhibitor of the PKC kinase or in 
combination or vehicle for controls (DMSO) in serum free conditions for 24 hours. When co-
treatment was applied BIM was added to the cells 1 hour before PMA or HGF Relative 
ABCC6 expression level was determined by quantitative PCR after normalization to the ABL 
housekeeping gene expression level as described in the methods. Expression levels are 
indicated as a percent of untreated control. Four parallels were used for each condition. The 
experiments were repeated three times, mean±SE *p<0.05  
This result suggested that the PKC family was able to inhibit the expression of 
ABCC6 but not all members were involved in this inhibition. Indeed the PKC 
family contains three subfamilies and it is known that the atypical subfamily is 
not inhibited by BIMI. Therefore we assumed that the atypical PKC subfamily 
was responsible for the inhibition observed after PMA treatment. 
Consequently, we asked whether that this inhibitory effect was MEK1/2 
dependent since it is also known that the atypical subfamily can activate the 
MEK1/2 cascade (Figure 2). 
4.1.3 ERK1/2 dependent down-regulation of ABCC6 
MEK1/2 is part of the ERK1/2 cascade and it is responsible for the 
phosphorylation and thereby the activation of the ERK1/2 kinase. In order to 
investigate the involvement of the ERK1/2 cascade in the regulation of 
ABCC6 expression, we used U0126, a specific inhibitor of the ERK1/2 
phosphorylation. We then performed a co-treatment of HGF and this inhibitor. 
We observed that the ERK1/2 inhibitor totally prevented the ABCC6 
expression inhibition due to HGF, pointing out the possible involvement of the 
ERK1/2 cascade in that inhibition.  
 
Figure 5. Inhibition of the ERK1/2 pathway precludes the downregulation of ABCC6 
expression. HepG2 cells were treated with PMA or HGF or U0126, a selective inhibitor of 
MEK1/2 kinase or in combination or vehicle for controls (DMSO) in serum free conditions for 
24 hours. When co-treatment was applied U0126 was added to the cells 1 hour before PMA or 
HGF. Relative ABCC6 expression level was determined by quantitative PCR after 
normalization to the ABL housekeeping gene expression level as described in the methods. 
Expression levels are indicated as a percent of untreated control. Four parallels were used for 
each condition. The experiments were repeated three times, mean±SE *p<0.05 
Next we asked whether the previously observed inhibition by PMA was also 
dependent on the ERK1/2 cascade. We performed co-treatment of PMA and 
U0126, and observed similar results than for the HGF co-treatment suggesting 
that the ERK1/2 cascade is responsible for the inhibition of the ABCC6 gene 
by PMA in HepG2 cells (Figure 5).  
We decided to rule out the possibility that the U0126 molecule was able to act 
in an ERK1/2 independent manner on the expression of the ABCC6 gene. 
Therefore we carried out an experiment with U0124, a compound structurally 
similar to U0126 but without any activity on the ERK1/2 cascade. Simple 
treatment of HepG2 cells with U0124 did not show any activation of ABCC6 
expression. On the contrary, U0126 activated the gene expression confirming 
that the observed prevention of the inhibition by U0126 was due to the action 
of the molecule on the MEK1/2 kinase cascade pointing out the potential role 
of ERK1/2 cascade in ABCC6 gene expression regulation (Figure 6). We 
considered the results obtained with U0124 sufficiently convincing not to try 
co-treatment of this molecule with HGF. 
 
Figure 6. U0126 molecule is not acting in an ERK1/2 independent manner on the expression 
of the ABCC6 gene. HepG2 or Caco2 cells were treated with U0126 or U0124 an inactive 
analog of U0126, or vehicle for controls (DMSO) in serum free conditions for 24 hours. 
Relative ABCC6 expression level was determined by quantitative PCR after normalization to 
the ABL housekeeping gene expression level as described in the methods. Expression levels 
are indicated as a percent of untreated control. Four parallels were used for each condition. 
The experiments were repeated two times, mean±SE *p<0.05.  
The ERK1/2 kinase exists in 2 different forms in the cells: the phosphorylated 
form, which represents the active kinases (ERK1/2-P), while the non-
phosphorylated form is inactive (ERK1/2). It is possible to detect by western 
immunoblot one or the other form with specific antibodies. Therefore, in order 
to further confirm the role of ERK1/2 in the observed inhibition, we tested the 
modification of the ratio of ERK1/2-P / ERK1/2 following treatment with the 
previously used molecules. In that purpose we performed a western blot and 
we analysed the ratio of ERK1/2-P / ERK1/2 by densitometry (Figure 7).  
 
Figure 7. Western blot analysis of ERK1/2 phosphorylation shows a correlation between the 
ERK1/2 activation and the ABCC6 transcriptional inhibition. a) HepG2 cells were treated 
with PMA or HGF or U0126, a selective inhibitor of MEK1/2 kinase or in combination or 
vehicle for controls (DMSO) in serum free conditions for 24 hours. When co-treatment was 
applied U0126 was added to the cells 1 hour before PMA or HGF. Proteins were extracted 
and 50ug protein was loaded per lane. The blotted membrane was incubated during 2 hours 
in the primary and subsequently 1 hour in the secondary antibody. b) Densitomentric analysis 
of the immunoblot shown in panel A (ERK-P/ ERK1/2 in arbitrary units).  
As expected, treatment with PMA or HGF led to more than four time increase 
in ERK1/2 phosphorylation in comparison to the control, while we observed 
an important decrease in the level of ERK1/2 phosphorylation after co-
treatment with HGF or PMA and U0126, emphasizing the role of ERK1/2 in 
the regulation of ABCC6 gene expression. 
4.1.4 Oxidative stress partially inhibits ABCC6 expression via the 
ERK1/2 pathway. 
The ERK1/2 cascade can be physiologically activated by various conditions in 
the cells (Kim and Choi). Therefore we inquired whether the regulation of 
ABCC6 by the ERK1/2 cascade was specific to its activation by the growth 
factors or if alternative activators were also able to inhibit ABCC6 such as the 
oxidative stress. We first performed treatments of HepG2 cells with different 
oxidative stress inducers, as tBHQ, vitamin K3, DFO, Cobalt, BNF and BSO. 
Interestingly, all the oxidative stress inducers led to the inhibition of ABCC6 
expression (Table 1). We then chose tBHQ and Vitamin K3 and performed co-
treatments with U0126. We observed that the co-treatment with the ERK1/2 
specific inhibitor at least partially prevented this inhibition (Figure 8).  
 
Figure 8. Oxidative stress inhibits ABCC6 expression partially via the ERK1/2 cascade. 
HepG2 cells were treated with tBHQ or Vitamin K3 or U0126 or related co-treatment or 
vehicle for controls (DMSO) in serum free conditions for 24 hours. Relative ABCC6 
expression level was determined by quantitative PCR after normalization to the ABL 
housekeeping gene expression level as described in the methods. Expression levels are 
indicated as a percent of untreated control. Four parallels were used for each condition. The 
experiments were repeated three times, mean±SE *p<0.05.  
Finally, to confirm the ERK1/2 phosphorylation/activation after treatment by 
the different ABCC6 inhibitors previously used, and to further confirm the role 
of ERK1/2 in this inhibition, we performed a western blot experiment on cells 
treated with different molecules. We observed that the quantity of the 
ERK1/2-P form increased after treatment with tBHQ or vitamin K3, while co-
treatment with U0126 partially prevented this increase (Figure 9). Due to the 
high background we were not able to perform quantitative densitometric 
analysis for any of these western blots, and therefore we were not able to 
determine the ERK-P/ERK ratio. 
 
Figure 9. Western blot analysis of ERK1/2 phosphorylation after oxidative stress induction. 
HepG2 cells were treated with tBHQ or Vitamin K3 or U0126 or vehicle for controls (DMSO) 
in serum free conditions for 24 hours. When co-treatment was applied U0126 was added to 
the cells 1 hour before PMA or HGF. Proteins were extracted and 50ug protein was loaded 
per lane. The blotted membrane was incubated during 2 hours in the primary and 
subsequently 1 hour in the secondary antibody.  
In conclusion our results showed that oxidative stress is an inhibitor of the 
expression of ABCC6 and (at least partially) this effect is due to the activation 
of the ERK1/2 kinase cascade. We decided not to investigate in further details 
the other mechanisms leading to the inhibition of ABCC6 expression by 
oxidative stress. Indeed oxidative stress can activate a multitude of different 
pathways in the cells that can be interconnected. We decided to focus on the 
interesting role of the physiological ERK1/2 pathway on the ABCC6 gene 
expression. 
4.1.5 ERK1/2 inhibits ABCC6 expression at the transcriptional 
level. 
Our next question was whether the observed effect was due to the down-
regulation of ABCC6 expression at the transcription initiation level, or to a 
post-transcriptional regulation by destabilization of the transcript. In order to 
rule out one of these two possibilities, we made use of a splice variant of 
ABCC6 named Up Regulated Gene 7 (URG7). This alternative transcript of 
ABCC6 was first observed in a screen for up-regulated genes following 
hepatitis B virus infection of HepG2 cells (Lian, Liu et al. 2001). Interestingly 
enough, URG7 shares the exact same promoter as ABCC6 but has a different 
3’UTR since URG7 ends in the second intron of the gene (Figure 10). This 
characteristic leads to different post-transcriptional regulatory mechanisms 
between ABCC6 and URG7 (the splicing and probably the mRNA stability 
too). We hypothesized that if p-ERK1/2 acts at the transcription initiation 
level, we should observe similar behavior of the two transcripts after treatment 
with the previously tested molecules. In contrast, if p-ERK1/2 acts at the post-
transcriptional level, we wouldn’t observe the same inhibition of URG7 after 
treatment with ABCC6 inhibitors.  
 
Figure 10. URG7 is an alternative transcript of ABCC6. 
 
Figure 11. ABCC6 expression is regulated via ERK1/2 at the transcriptional level. HepG2 
cells were treated with PMA, HGF and U0126, and related co-treatment or vehicle for 
controls (DMSO) in serum free conditions for 24 hours. Relative ABCC6 and URG7 
expression levels were determined by quantitative PCR after normalization to the ABL 
housekeeping gene expression level as described in the methods. Expression levels are 
indicated as a percent of untreated control. Four parallels were used for each condition. The 
experiments were repeated three times, mean±SE *p<0.05.  
Treatments of HepG2 cells with PMA, HGF (Figure 11), tBHQ and vitamin 
K3 (data not shown), and the respective co-treatments with U0126 showed the 
same effect on the expression level of ABCC6 and URG7, strongly suggesting 
that the ERK1/2 cascade inhibits the expression of ABCC6 gene at the 
transcription initiation level. 
4.1.6 De novo protein synthesis is not needed for the down-
regulation of ABCC6 by the ERK1/2 cascade 
Our results strongly suggested that the ABCC6 expression inhibition by the 
ERK1/2 cascade was at the transcriptional level. In the following experiment 
we investigated the mechanism of this regulation, and more precisely whether 
the ERK1/2 action on ABCC6 expression needs a new protein synthesis or not. 
To answer this question, we performed treatments of HepG2 with 
Cycloheximide, an inhibitor of the protein synthesis, with or without PMA 
selected for its ERK1/2 dependent high inhibitory effect of ABCC6 
transcription regulation. We assumed that if the ERK1/2 effect was direct then 
co-treatment with PMA and cycloheximide wouldn’t show any differences 
with PMA treatment alone. In that purpose we treated HepG2 cells with 
cycloheximide three hours before adding PMA, and inversely. The idea was to 
stop the de novo protein synthesis before inducing the ERK1/2 cascade, and if 
de novo synthesis was needed to observe an important difference between the 
two conditions.  
Surprisingly we observed that treatment with cycloheximide alone led to the 
induction of ABCC6 expression (Figure 12). Intriguingly URG7 expression 
wasn’t induced but inhibited by cycloheximide. This is the first and only time 
that we observed regulatory differences between the two alternative 
transcripts. However our results also showed no difference between PMA 
treatment and co-treatment with PMA and cycloheximide. It is necessary to 
stress that the differences observed between URG7 and ABCC6 regulation 
after simple treatment with cycloheximide made impossible to conclude on 
that experiment, even if the co-treatment results highly suggested that the 
regulation of ABCC6 expression by the ERK1/2 cascade is not dependent on 
de novo synthesis of protein in the HepG2 cell line. 
 
Figure 12. ERK1/2 regulates the expression of ABCC6 without the needs for de novo protein 
synthesis. HepG2 cells were treated with PMA or cycloheximide (CHX) an inhibitor of the 
protein synthesis, or vehicle for controls (DMSO) in serum free conditions for 24 hours. PMA 
or CHX were added 2 hours before in case of co-treatment. Relative ABCC6 expression level 
was determined by quantitative PCR after normalization to the ABL housekeeping gene 
expression level as described in the methods. Expression levels are indicated as a percent of 
untreated control. Four parallels were used for each condition. The experiments were 
repeated three times, mean±SE *p<0.05. 
4.1.7 ERK1/2 effect is cell type specific and its response element is 
located in the proximal promoter of ABCC6.
Altogether our results showed that ERK1/2 activation in HepG2 cells seems to 
down-regulate ABCC6 expression at the transcription initiation level. To 
identify the regulatory element(s) involved we carried out luciferase reporter 
gene assay. First we tested the promoter region of ABCC6 to locate the 
sequence in the proximal or distal promoter. Indeed it has been shown that the 
distal promoter contains an inhibitory element (Aranyi, Ratajewski et al. 
2005). After transfection of HepG2 cells with the promoter construct we 
treated the cells with PMA, or U0126. We observed that the distal and the 
proximal promoters showed similar variation of the luciferase activity 
following the treatment with the ERK1/2 inducer or inhibitor. This result 
clearly pointed out the role of the proximal promoter in this regulation (Figure 
13).  
 
Figure 13. ERK1/2 response element is located in the proximal promoter of the ABCC6 gene. 
Distal (-718/+72) and proximal (-332/+72) promoter constructs were transiently transfected 
to HepG2 cells. 24 hour after the transfection cells were treated with PMA or U0126 at the 
indicated concentrations or vehicle. Cells were treated with the compounds for 24 hours and 
promoter activity was then measured by luciferase assay. Results of the assay were 
standardized against control reporter activity (pCMV-SEAP) and expressed as fold induction 
over control value (activity of empty vector (pGL3-basic) in control treated cells), mean±SE 
(n = 5), *p<0.05.  
Next we continued by confirming the ERK1/2 dependence of that inhibition. 
We co-transfected our cells with the -332/+72 construct and a constitutively 
active MEKK1 (MEKK1ca) that phosphorylates and thus activates the 
ERK1/2 kinase cascade, or a dominant negative ERK1 (ERK1dn) that inhibits 
the cascade. Both MEKK1ca and ERK1dn acted on the -332/+72 construct in 
a dose dependent manner (Figure 14 A and B), demonstrating and confirming 
the role of the ERK1/2 cascade in the inhibition of ABCC6 expression at the 
transcription level via the proximal promoter of the gene.  
 
 
Figure 14a. Dose-response effect of the overexpression of constitutively active MEKK1 
(MEKKca) on the transcriptional activity of ABCC6 promoter in HepG2 cells. Results after 
standardization were expressed as fold induction over control value (activity of empty vector 
(pGL3-basic co-transfected with MEKKca or pCMV-XL5 empty expression vector), mean±SE 
(n=5), *p<0.05. b. Dose-response effect of the overexpression of dominant negative ERK1 
(ERK1dn) on the transcriptional activity of ABCC6 promoter in HepG2 cells. Results after 
standardization were expressed as fold induction over control value (activity of empty vector 
(pGL3-basic) co-transfected with ERK1dn or pCMV-XL5 empty expression vector, mean±SE 
(n = 5), *p<0.05.  
Then we asked whether the observed effect was tissue/cell line specific or not, 
since it is known that ABCC6 has tissue specific expression. In that purpose 
we used HeLa cells that do not express ABCC6 and we transfected the cells 
with the proximal promoter -332/+72 construct. We then performed treatments 
using the following protocol. Twenty-four hours after seeding HepG2 cells on 
a 96 well plate, we transfected them with the constructs of interest (here the -
332/+72 construct). After another 24h we performed treatment with the same 
concentration of molecules than previously. With this protocol we performed 
various treatments activating the ERK1/2 cascade. We did not observe any 
decrease or increase in the luciferase activity after the treatments. Our results 
clearly demonstrated that the ERK1/2 response is tissue specific since no 
inhibitory effect was observed after treatment with PMA, HGF, EGF or 
U0126 on the HeLa model cell line (Figure 15).  
 
Figure 15. the ERK1/2 response is cell type specific. Wild-type ABCC6 luciferase construct 
was treated with PMA, HGF, EGF, U0126 or vehicle (DMSO) at the indicated concentrations 
for 24hours in HeLa cells. Results of the assay were standardized against control reporter 
activity (pCMV-SEAP) and expressed as fold induction over control value (activity of empty 
vector (pGL3-basic) in control treated cells), mean±SE (n = 5). 
Altogether we showed in these experiments that the ERK1/2 inhibits ABCC6 
at the transcription initiation level. Also we demonstrated that the ERK1/2 
dependent response element is located in the proximal promoter of the ABCC6 
gene and that this element exhibits tissue specificity.  
4.1.8 Localization of the ERK1/2 response element in the proximal 
promoter of ABCC6. 
In our further experiments we wished to locate the ERK1/2 response element 
in the ABCC6 gene, using previously characterized constructs that map the 
proximal promoter of the gene (Figure 16).  
 
Figure 16. Reporter plasmids containing serial deletions of the human ABCC6 gene promoter. 
Numbering starts at the translation start site.  
As previously observed the -145/+72 construct showed a low basal promoter 
activity, while the -209/+72 was slightly more active and the -234/+72 
construct harbored a strong activatory element.  
 
Figure 17. The ERK1/2 cascade element is located in the proximal promoter of ABCC6 gene 
between -209 and -145 bp. Different promoter constructs were transiently transfected to 
HepG2 cells. 24 hour after the transfection cells were treated with PMA or EGF or HGF at 
the indicated concentrations or vehicle. Cells were treated with the compounds for 24 hours 
and promoter activity was then measured by luciferase assay. Results of the assay were 
standardized against control reporter activity (pCMV-SEAP) and expressed as fold induction 
over control value (activity of empty vector (pGL3-basic) in control treated cells), mean±SE 
(n = 5), *p<0.05.  
We then performed treatments using the same conditions than previously, and 
we tested the effect of HGF, PMA and EGF for their ability to inhibit ABCC6 
expression at the promoter level (Figure 17). We observed similar inhibitory 
effects on the constructs activity for all constructs extending in the 5’ region of 
the promoter beyond position -145 (50%, 70% and 30% inhibition 
respectively). In conclusion, we identified the ERK1/2 dependent regulatory 
region in the ABCC6 proximal promoter between -209 and -145bp from the 
translation initiation site. 
Using luciferase assay we previously demonstrated the crucial role of the         
-209/-145bp region in the regulation of ABCC6. This region contains two 
PLAG like (one PLAG1 and one PLAGL1) transcription factor binding sites 
that we previously showed to play a role in the up-regulation of ABCC6. 
Moreover, we demonstrated that this region is responsible for the tissue 
specific regulation of ABCC6 since mutations within the region, between the 
two PLAG binding sequences, led to a total loss of activity of the proximal 
promoter construct, in a tissue specific manner. Indeed the increased activity 
of the construct containing the -209/-145 region in comparison with the -
145/+72 region, was observed only in the ABCC6 expressing cell lines Hep3B 
and HepG2. In contrast, no difference in the luciferase activity was detectable 
between the different constructs in the A549 and the HEK193 cell lines that do 
not express ABCC6. Similarly, mutation between the two PLAG consensuses 
led to a loss of the luciferase activity in the HepG2 and Hep3B cell lines. We 
interpreted this effect as the PLAG factor stabilizing an unidentified 
transcription factor responsible for the tissue specific expression of the ABCC6 
gene. (Ratajewski, de Boussac et al. 2009).  
Our experiments presented here described a tissue specific response element 
dependent on the ERK1/2 cascade that is located in the same 60bp region than 
the unidentified tissue specific factor. We hypothesized that the two factors 
identified in the two studies might be the same, therefore, we performed more 
detailed in silico analysis of the -209/-145 region. Several independent lines of 
evidence suggested that the hepatocyte nuclear factor 4α (HNF4α) might be a 
good candidate for the unidentified liver-specific factor. In order to examine if 
the ERK1/2 cascade is exerting its activity via this site, we made use of 
constructs previously used of the proximal promoter region with specific 
mutation inside the HNF4alpha putative binding site, or in the PLAG1 binding 
site located next to the HNF4alpha element.  
The construct m1(-332/+72) contains a mutated PLAG site, while the 
construct m3(-332/+72) harbors a stretch of mutation between -155 and -158 
(Figure 18).  
 
Figure 18. Reporter plasmids containing serial deletions of the human ABCC6 gene 
promoter. Numbering starts at the translation start site.  
We performed treatment on -332/+72, m1 or m3 transfected HepG2 cells with 
ERK1/2 cascade modulators HGF, PMA, EGF, and U0126. Interestingly, the -
332/+72 and the m1 constructs reacted in a similar way to the ERK1/2 
modulators in the HepG2 cells even if the m1 construct had a decreased 
luciferase activity by approximately 20% in comparison to the wild type 
construct. In contrast, an activity similar to the -145/+72 construct, which was 
not responsive to the ERK1/2 cascade, could be detected with the m3 
transfected HepG2 cells showing the essential role of the HNF4alpha biding 
site in the ERK1/2 inhibition of ABCC6 expression (Figure 19).  
 
Figure 19. A mutation in a HNF4alpha binding consensus in the proximal promoter of the 
ABCC6 gene prevent the ERK1/2 inhibitory effect. Different promoter constructs (wt, m1, m3) 
were transiently transfected to HepG2 cells. 24 hour after the transfection cells were treated 
with PMA or EGF or HGF at the indicated concentrations or vehicle. Cells were treated with 
the compounds for 24 hours and promoter activity was then measured by luciferase assay. 
Results of the assay were standardized against control reporter activity (pCMV-SEAP) and 
expressed as fold induction over control value (activity of empty vector (pGL3-basic) in 
control treated cells), mean±SE (n = 5), *p<0.05.  
4.1.9 The ERK1/2 cascade inhibits the HNF4a induction of ABCC6 
expression.  
Finally, we tested the hypotheses that HNF4alpha is responsible for the 
ABCC6 tissue specific expression, and that the ERK1/2 cascade modulates this 
transcription factor. It is known from the literature that HeLa cell line is 
expressing neither the HNF4alpha transcription factor nor the ABCC6 gene 
(Sladek, Zhong et al. 1990). Therefore, we transiently transfected HeLa cells 
with the HNF4alpha transcription factor, and with the wild type -332/+72, the 
m1 or the m3 ABCC6 proximal promoter constructs. We observed no 
induction of the luciferase activity after transfection of the wild type promoter 
construct alone (neither with m1 or m3), In contrast, and as we predicted, the 
HNF4alpha transcription factor increased the wild type proximal promoter 
luciferase activity to a similar level that the wild type proximal promoter 
activity in HepG2 cells (Figure 20), showing that HNF4alpha is up-regulating 
the expression of ABCC6 by acting on the proximal promoter of the gene. 
Moreover a similar (but reduced of about 20% compared to the wild type) 
induction was observed when HNF4alpha was co-expressed with the m1 
proximal promoter construct (mutated at the PLAG site) showing that the 
PLAG site is not responsible for the HNF4alpha induction. Finally, co-
expression of the HNF4alpha transcription factor, and the m3 construct 
(mutated at the HNF4alpha binding site) in HeLa cells did not lead to any 
variation of the luciferase activity compared to the control. Therefore we 
concluded that HNF4alpha has an important role in the ABCC6 up-regulation.  
 
Figure 20. HNF4a upregulates ABCC6 expression in an ERK1/2 dependent manner and 
confers tissue-specificity. Luciferase reporter gene assay in HeLa cells. Wild-type, m1 and m3 
constructs were co-transfected with HNF4α, MEKKca or both or pCMV-XL5 empty 
expression vector. Results after standardization were expressed as fold induction over control 
value (activity of empty vector (pGL3-basic co-transfected with the corresponding expression 
vectors), mean±SE (n = 5), *p<0.05 – statistically different from cells transfected with control 
empty vector (CMV-XL5), #p<0.05 – statistically different from cells transfected with HNF4α 
expression vector. 
Next we wanted to observe in HeLa cells if ERK1/2 modulates HNF4alpha 
and consequently ABCC6 gene expression. For this purpose, we co-transfected 
HNF4alpha, the proximal promoter construct, and the MEKKca that 
constitutively activates the ERK1/2 cascade. Our hypothesis was that the 
ERK1/2 cascade down-regulates the ABCC6 gene expression via the 
HNF4alpha modulation. In such a case the co-transfection of MEKK1ca and 
HNF4alpha with the proximal promoter construct would lead to a decrease in 
the luciferase activity compared to the HNF4alpha co-transfected alone with 
the proximal promoter. As expected, we observed that the constitutive 
activation of the ERK1/2 cascade by MEKK1ca in HeLa cells was sufficient 
to totally prevent HNF4alpha induction of ABCC6 (Figure 20). This last result 
showed that the ERK1/2 cascade activation down-modulates the HNF4alpha 
transcription factor dependent regulation of ABCC6.  
To prove the binding of HNF4alpha to the ABCC6 proximal promoter in its 
chromatin environment, we performed chromatin immunoprecipitation (ChIP) 
(the ChIP experiment was performed in Lodz by Iwona Sachrajda). By 
investigating different conditions using HGF and PMA treatments, we also 
tested the ERK1/2 dependent binding of HNF4alpha to the promoter (Figure 
21).  
 
Figure 21. Chromatin immunoprecipitation of HNF4a show the ERK1/2 dependent binding of 
the factor to the ABCC6 promoter in HepG2 cells. HepG2 cells were treated with PMA or 
HGF at the indicated concentrations or vehicle for 24 hours. Amount of immunoprecipitated 
cognate gene promoter sequences was determined by real-time PCR and expressed in 
arbitrary relative values, standardized against amount of input material (means±SEM., n=4). 
*statistically significant at p<0.05. 
As we suspected, HNF4alpha bound to the ABCC6 promoter in control 
condition. In contrast, and as our previous results suggested, treatment with 
HGF or PMA, leading to the ERK1/2 cascade activation, reduced dramatically 
(30-50%) the HNF4alpha bound protein on the ABCC6 promoter, while no 
binding differences could be observed for the GAPDH promoter used as 
control. This final experiment pointed out the unique role of HNF4alpha in the 
regulation of ABCC6, and showed that HNF4alpha binding to the promoter is 
under the negative modulation of the ERK1/2 cascade. 
 
Figure 22. Schematic presentation of ABCC6 expression regulation by the ERK1/2 pathway. 
ERK1/2 kinase pathway is represented in circles, as well as the HNF4α transcription factor. 
Arrows indicate positive regulations. 
In conclusion, we demonstrated that the ERK1/2 cascade down-regulates the 
expression of ABCC6 at the transcription initiation level. We first identified 
the ERK1/2 response element in the proximal promoter of the gene and we 
demonstrated that this element is tissue sensitive. Next we showed that the 
HNF4alpha transcription factor can bind to that sequence, and activate the 
transcription of the human ABCC6 gene, therefore demonstrating that 
HNF4alpha is a master regulator of the ABCC6 gene. Finally we revealed that 
the ERK1/2 cascade negatively modulates the HNF4alpha transcription factor 
leading to the down regulation of the ABCC6 gene expression (Figure 22). 
4.2 Identification of an enhancer in the first intron of the 
ABCC6 gene 
4.2.1 DNase I technique 
The essential role of HNF4alpha in the regulation of the ABCC6 gene 
expression was uncovered by the study of the proximal promoter of ABCC6. 
We simultaneously completed the transcriptional regulation studies of ABCC6 
by using a different approach as well.  
DNase I Hypersensitivity assay (DHA) reveals the regulatory elements as 
enhancers and active promoter regions by preferential digestion of open 
chromatin loci (Eissenberg, Cartwright et al. 1985). The major advantage of 
this technique is that it identifies the presence of regulatory elements in a 
hypothesis free context by screening a large genomic DNA (gDNA) fragment. 
The DNase I will first digest sensitive region of the DNA, therefore the 
principle is to perform a dose dependent partial digestion of the gDNA and 
then to reveal, using Southern blot or qPCR techniques, the appearance of 
different hypersensitive sites (Cai, Struk et al.).  
We decided to apply this technique to the ABCC6 promoter. ABCC6 is in a 
head to head orientation with the NOMO3 gene and they are separated by a 10 
kilobase pairs (kb) region containing both proximal promoters (Figure 23). 
Since it has been shown that majority of the HS are located within 10 kb 
around the transcription initiation site (Sabo, Humbert et al. 2004) we focused 
on that 10kb intergenic region. 
 
Figure 23. Chromosomal localization of the ABCC6 gene.  
ABCC6 shares more than 99% identity with its two pseudogenes in the 
promoter region. Our strategy was to segregate the two pseudogenes and the 
ABCC6 gene by using restriction enzyme site differences between the two 
ABCC6-pseudogenes and the ABCC6 gene promoter. More precisely, by using 
a probe located between the two restriction enzyme sites and in the region 
common to the three ABCC6 like promoters, we would be able to segregate 
the pseudogenes to the ABCC6 gene by performing double restriction enzyme 
digestion on the gDNA (if the pseudogenes probe is between both restriction 
enzymes sites), and in order to find the restriction enzymes we performed an 
in silico screen of the promoter region of ABCC6 and the two pseudogenes 
(Psi1 and Psi2)  
We found that the BglII restriction enzyme has a different pattern of digestion 
for the ABCC6 gene and the two pseudogenes in the region of interest. Indeed 
the two pseudogenes contain one additional BglII restriction site in 
comparison with the ABCC6 gene (Figure 24). We also located a NcoI 
digestion site present in all three promoters at 150bp from the BglII sites. Thus 
theoretically, after gDNA digestion by the two restriction enzymes and 
Southern blot with a specific probe recognizing the 150bp region located 
between the NcoI and the BglII restriction enzyme sites, we would observe a 
5.6kb band representing specifically the ABCC6 gene fragment (Figure 24). 
 
Figure 24. Mapping of the NOMO3 – ABCC6 intergenic region with the BglII restriction 
enzyme sites and the P61 probe. 
The probe design was a challenge. Indeed the 5’ upstream sequence of the 
ABCC6 gene contains highly repeated sequences. Then, considering the 
localization restrictions due to the restriction enzyme sites and these repeated 
elements, we needed to limit the probe (called P61) size to a 196 bp length, 
and moreover, we were not able to design the probe without the NcoI 
restriction site, that is located at 30bp from the 5’ end of P61 (figure 24).  
All experiments were carried out on the ABCC6 expressing cell line HepG2 if 
not specified. Please note that weak signals observed on films are very 
difficult to see on film photography. In our pilot experiments we first tried 
BglII and NcoI enzymes alone to see whether we were able to observe any 
hypersensitive sites. Thus we first used only the BglII digestion, with this 
enzyme alone we knew that a hypothetical HS site observable after Southern 
blot with a size of less than 4.5kb could have for origin the ABCC6 gene or the 
two pseudogenes. Indeed, with this example 2 HS sites could be present on the 
PXE gene around the P61 probe, and then the Southern blot would reveal the 
fragment, while only one HS site would be necessary for the two pseudogenes. 
Therefore we wouldn’t be able to locate and segregate the different HS sites 
(Figure 25). However we simply wanted to see if we were able to detect any 
HS sites. Southern blot performed after digestion with the BglII restriction 
enzymes did not reveal any clear hypersensitive site (Cai, Struk et al.) band(s). 
 
Figure 25. DNase I digestion of HepG2 gDNA in the HepG2 cell line. Whole cells were 
submitted to a DNase I partial digestion during 3 minutes with 0; 2.5; 5; 7.5; 10 or 12.5 μg 
DNase I. gDNA was extracted and 20ug were digested with the BglII restriction enzyme. 
Southern blot with the P61 probe revealed a 10kb (ABCC6) and a 4.5kb (ABCC6-like) 
fragment.  
In the next pilot experiment we tested the NcoI digestion alone which releases 
a 7.2kb fragment that does not discriminate between the 3 ABCC6-like genes. 
We assumed that if we can detect any HS with this strategy, we would next 
perform the double BglII/NcoI digestion to analyze the PXE gene alone. With 
this strategy we were able to identify a HS site at 5kb (Figure 26).  
 
Figure 26. Southern Blot revealed a hypersensitive site at 5.5kb in the HepG2 cell line. Whole 
cells were submitted to a DNase I partial digestion during 3 minutes with 0; 6; 7; 8 or 10 μg 
DNase I. gDNA was extracted and 20ug were digested with the NcoI restriction enzyme. 
Southern blot with the P61 probe revealed a 7.2kb (ABCC6), a 11kb (NOMO3) fragment and 
a 5.5kb hypersensitive site. 
Surprisingly, we also observed a higher band around 12kb. We thought when 
we designed the P61 probe that the 30bp part located on the 5’ part of P61 
wouldn’t be sufficient to reveal a fragment by Southern blot. That 12kb extra 
band observed showed us that unexpectedly we were wrong. Thus, after NcoI 
digestion two regions were visible: the 11.7kb region on the 5’ of P61 and the 
7.2kb region on the 3’ part of the P61. The analysis of the identified HS site at 
5kb was then complicated. Indeed the HS site could be located either in the 
first intron of NOMO3 if it was revealed by the 30bp in the 5’end of P61, as 
well as in the proximal promoter of ABCC6 if it was revealed by the 170bp in 
the 3’ part of P61 (Figure 27). 
 
Figure 27. Mapping of the NOMO3 – ABCC6 intergenic region with the NcoI restriction 
enzyme sites and the P61 probe. 
Considering the experimental challenges, we decided to further analyze the 5’ 
part of the ABCC6 gene without discriminating the three ABCC6 like genes. 
After the identification of regulatory region our strategy included the 
following analysis of the different HS sites by Luciferase assay by cloning the 
PXE promoter. Then Luciferase assay investigation would give us leads to 
identified transcriptional regulatory elements. The high identity between the 
three ABCC6-like genes was anyway preventing us from analyzing the ABCC6 
gene alone in a simple way. 
4.2.2 DNase I assay revealed an active genomic region 
In order to precisely map the HS sites observed in the preliminary experiment, 
we performed new in silico analysis of the region containing both NcoI HS 
sites previously observed, and we selected the BsmI restriction enzyme. BsmI 
cuts in the first intron of the NOMO3 gene and in the second intron of the 
ABCC6 gene, and liberates a 17kb fragment. We then designed a new probe 
P62 recognizing the 3’ end of the first intron of ABCC6, to reveal this 
fragment by Southern blot. The P62 probe location in the first intron of the 
gene would allow us to screen ABCC6 region with high accuracy (Figure 28).  
 
Figure 28. Mapping of the NOMO3 – ABCC6 intergenic region with the BsmI and the NcoI 
restriction enzyme sites and the P62 probe.  
We performed Southern blot using these experimental conditions, and we 
observed three HS sites with bands at 11kb, 2.2kb and 1.8kb (Figure 29). We 
located the HS site at 11kb inside the first intron of NOMO3 and the two other 
sites close to the translation initiation site of ABCC6.  
 
Figure 29. Southern Blot revealed three hypersensitive sites at 11, 2.2 and 1.8Kb from the P62 
probe in the HepG2 cell line. Whole cells were submitted to a DNase I partial digestion 
during 3 minutes with 0; 9; 11; 13; 15 or 17 μg DNase I. gDNA was extracted and 20ug were 
digested with the BsmI restriction enzyme. Southern blot with the P62 probe revealed a HS 
band at 11kb from P62 in the first intron of NOMO3 gene and two HS at 2.2 and 1.8kb from 
P62, in the proximal promoter and the first intron of the ABCC6 gene.  
Next we decided to investigate further these two HS sites located close to the 
translation initiation site (ATG) of ABCC6. In that purpose we found by in 
silico analysis another restriction enzyme (NspI) that allowed us to narrow 
down the screened region to a 4.7kb DNA fragment containing the first intron 
and the proximal promoter of ABCC6. DHA analyzed by this higher resolution 
Southern blot showed that the two HS sites previously identified around the 
ATG of ABCC6 were in fact three different HS sites, represented in the 
Southern blot by bands at 2.2kb, 1.7kb and 1.3kb. We named the HS sites 
from 5’ to 3’, HS1 to HS3 (Figure 30).  
 
 
Figure 30. Southern Blot revealed three hypersensitive sites at 2.2, 1.7 and 1.3Kb from the 
P62 probe in the HepG2 cell line. Whole cells were submitted to a DNase I partial digestion 
during 3 minutes with 0; 11; 13; 15 or 17 μg DNase I. gDNA was extracted and 20ug were 
digested with the NspI restriction enzyme. Southern blot with the P62 probe revealed three HS 
sites close to the ATG of the ABCC6 gene. One in the proximal promoter (HS1, band at 
2.2kb) and two in the first intron of the gene (HS2 band at 1.7, and HS3 band at 1.3kb). 
Both the DNase digestion and our Southern blot conditions have a resolution 
of 150bp thus we located HS1 in the proximal promoter of the ABCC6 gene 
between -200bp and -50bp, HS2 in the first intron of ABCC6 between +310 
and +460bp and HS3 as well in the first intron of ABCC6 but HS3 between 






























































Figure 31. Genomic sequence of ABCC6 with the localization of HS1, HS2 and HS3. 
GCATGT/GCATGC: NspI site; GAAC: exons; TGTTTTCA: Hypersensitive sites 
4.2.3 Hypersensitive sites are tissue-specific 
As ABCC6 has tissue specific expression, we expected that we would be able 
to observe tissue specificity for those three HS sites. We used in that purpose 
three other human cell line models selected for their level of expression of the 
ABCC6 gene. The Caco2 cell line is a colorectal adenocarcinoma cell line. 
This cell line is used as a model of intestinal epithelial cell. It is well known 
that when these cells reach confluency a differentiation process starts (Singh, 
Dai et al. 1996). We first demonstrated that during this process, the level of 
ABCC6 expression increased by 2 to 4 times reaching the same level of 
ABCC6 expression observed in the HepG2 cell line. We therefore decided to 
use this cell line as a model for the ABCC6 expression regulation studies.  
HEK293 cells are originating from an embryonic kidney. HeLa is an 
adenocarcinoma cell line. Previously we used HEK293 cells as a model 
(Aranyi, Ratajewski et al. 2005) but in that previous study we confirmed 
expression of the ABCC6 gene by PCR, while here we analyzed its expression 
by quantitive PCR showing more precise results. As expected, HeLa did not 
express ABCC6 at a detectable level. More surprisingly similar results were 
obtained with the HEK293 cell line, while we expected this kidney cell line to 
express the gene (not shown). We decided to use these cell lines as negative 
control.  
DHA performed on those cell lines showed interesting results. Indeed, while 
HS1, HS2 and HS3 were detected after Southern blot for the HepG2 and the 
Caco2 cell lines, no hypersensitive sites were observable for HeLa and HEK. 
We therefore performed a BsmI digestion followed by a Southern blot with the 
P62 in order to confirm the digestion by the DNase I for these two cell lines. 
Again we did not observe any HS near by the ABCC6 ATG while the NOMO3 
HS was visible, indicating that HS1, HS2 and HS3 are tissue specific (Figure 
32). These data suggest a link between the observed HS sites and the ABCC6 
expression. 
 
Figure 32. The three HS sites are tissue specific. Whole cells were submitted to a DNase I 
partial digestion during 3 minutes with 0; 5; 10; 15 or 20 μg DNase I in the case of Caco2 
cells, 0; 15; 20; 25 or 30 μg DNase I in the case of HeLa and HEK293 cells. gDNA was 
extracted and 20ug were digested with the NspI restriction enzyme for the Caco2 cells, and 
BsmI for HeLa and HEK293. Southern blot with the P62 probe revealed HS1, HS2 and HS3 
for the Caco2 cell line, and do not reveal HS sites nearby the ATG of ABCC6 for the HeLa 
and HEK293 cell lines.  
4.2.4 Mapping of the HS sites in the proximal promoter and the 
first intron. 
In the following experiment we investigated the functionality of the different 
HS sites and more specifically we focused on the two intronic HS sites by 
luciferase assay. Indeed we assumed from the localization of the HS1 in the 
proximal promoter that it marks the binding of HNF4alpha. We mapped by 
luciferase assay the different HS sites, with constructs starting at -332 and 
progressively truncated in the 3’ ends from +960 as follows: -332/+960; -
332/+817; -332/+716; -332/+688; -332/+629; -332/+513 (Figure 33).  
 
Figure 33. HS3 is located between +629 and +688 from the ATG of ABCC6. Different 
luciferase constructs were transiently transfected to HepG2, Caco2, HEK293 or HeLa cells. 
Results of the assay were standardized against control reporter activity (pCMV-SEAP) and 
expressed as fold induction over control value (activity of the empty vector pGL3-basic), 
mean±SE (n = 5), *p<0.05  
Interestingly the activity of -332/+960 was approximately 8 times higher than 
the activity of the proximal promoter -332/+72. However an important loss of 
luciferase activity was observed with the -332/+629 construct, while the -
332/+688 construct still demonstrated a similar activity to the -332/+960 
construct. Finally no loss of activity was observed between the -332/+629 and 
the -332/+513 constructs, we then located the HS2 between +72/+513bp 
(Figure 33). These results suggested the localization of the different HS sites. 
Thus we confirmed the location of the HS2 between +310 and +460 since no 
loss of activity was observed 5’ of the position +629. Moreover we revealed 
the important transcriptional induction role of HS3, overlapping with the 
region between +629 and +688bp. 
4.2.5 The intronic hypersensitive sites act as enhancers 
Next we wished to study in more details the mechanism of action of the 
intronic HS elements, and whether the intronic HS sites uncovered an 
alternative second promoter or enhancer. We assumed that if the intronic 
hypersensitive sites act as strong alternative promoters, we should detect a 
similar activity between constructs that contained the intronic hypersensitive 
sites of ABCC6 without the proximal promoter and the -332/+960 construct. 
Inversely if the intronic hypersensitive sites act as enhancers, the activity of 
these constructs should be close to the empty vector. Thus we designed the 
following constructs containing the HS2 site alone (+72/+629), the HS2 and 
HS3 sites together (+72/+688) or the HS3 alone (+479/+960) (Figure 34). We 
measured the luciferase activity of the constructs. No luciferase activity could 
be detected with any of the tested constructs in contrast to the -332/+72 
construct containing the proximal promoter of ABCC6. We therefore 
concluded that the two intronic hypersensitive sites act as enhancers in the 
ABCC6 gene.  
 
Figure 34. HS2 and HS3 are acting as enhancers and are not marking a second promoter of 
the ABCC6 gene. Different luciferase constructs were transiently transfected to HepG2 and 
Caco2 cells. Results of the assay were standardized against control reporter activity (pCMV-
SEAP) and expressed as fold induction over control value (activity of the empty vector pGL3-
basic), mean±SE (n = 5), *p<0.05 
We next investigated the possible connections between the proximal promoter 
of ABCC6 and the intronic hypersensitive sites. First we examined the HS2 
site. As expected, the luciferase assay showed the same activity of the -
145/+72 construct in HeLa and HepG2 cells and the -332/+72 constructs had 
higher activity in HepG2 cells (Figure 35), showing the presence of a tissue 
specific element in the -332/-145 region, due to the HNF4alpha binding site 
located around -160bp.  
Interestingly, while the luciferase activity of the -332/+72 was 10 times higher 
in HepG2 than in HeLa, we observed comparable activity of the -332/+629 
construct in both cell lines suggesting an interaction between the HS2 and the 
minimal -145/+72 promoter in HeLa cells (Figure 35).  
 
Figure 35. HS2 is connected to the -145/+72 minimal constitutive promoter of the ABCC6 
gene. Different luciferase constructs were transiently transfected to HepG2 and HeLa cells. 
Results of the assay were standardized against control reporter activity (pCMV-SEAP) and 
expressed as fold induction over control value (activity of the empty vector pGL3-basic), 
mean±SE (n = 5), *p<0.05 
Moreover, when we tested the activity of the following constructs, -145/+72; -
145/+629 and compared them with the -332/+72; -332/+629 constructs in 
HepG2 and Caco2 cells (Figure 36).  
 
Figure 36. HS3 is connected to the -332/-145 region of the proximal promoter of ABCC6. 
Different luciferase constructs were transiently transfected to HepG2 and Caco2 cells. Results 
of the assay were standardized against control reporter activity (pCMV-SEAP) and expressed 
as fold induction over control value (activity of the empty vector pGL3-basic), mean±SE (n = 
5), *p<0.05 
We observed that the HS2 enhances the luciferase activity when the upstream 
sequence from -145 is not present since the activity of the -145/+629 construct 
was almost three times more important than the activity of the -145/+72 
construct while no difference in the luciferase activity could be detected 
between the -332/+72 and the -332/+629 constructs.  
Finally, these results showed that the region containing the HS2 between +72 
and +629 exhibits an enhancer activity without tissue specificity. 
Nevertheless, the HS2 does not show any enhancer activity if the -332/-145 
region is active. Finally the results suggested a connection between the 
minimal promoter of the gene (-145/+72) and the HS2. This last result may 
indicate that the HS2 takes part in the basal expression of the ABCC6 
expression. 
Then we wondered about the interaction between the proximal promoter of the 
gene and the HS3 site. In that purpose, we compared in the HepG2 and Caco2 
ABCC6 expressing cells the constructs: -145/+72; -145/+629; -145/+688; -
332/+72; -332/+629 and -332/+688 containing or not the HNF4apha binding 
site (Figure 36). As already shown we observed that the presence of all three 
hypersensitive sites together (-332/+688) greatly enhanced the luciferase 
activity. Indeed the activity of this construct was dramatically increased in 
contrast with the -145/+688 construct (Figure 36). In conclusion these results 
showed the important role of the HS3 on the induction of the ABCC6 
expression, and revealed the probable link between the proximal promoter of 
the gene and HS3. 
4.2.6 Localization of the enhancer activity inside the 60bp of the 
HS3 
We next wanted to clarify the organization of the HS3 site, and to identify the 
sites responsible for the enhancement of the promoter activity. First, we 
performed in silico analysis of the 60bp containing the HS3 site. Only few 
transcription factor binding sites were suggested on the sequence, and three of 
them were liver enriched factors (C/EBP, HNF3 and HLF) (Figure 37).  
 
Figure 37. In silico analysis of the 78bp region of the HS3. We submitted the 78bp sequence 
containing the 60bp region of the HS3, plus 18bp located at the 5’ end of the region to 
different on line transcription factor screening software (P-MATCH; MatInspector; 
TFSEARCH). The position +652 is indicated in red. 
We first tested the different identified factors by co-expressing them with our -
332/+688 construct in HeLa cells. Obviously with our current knowledge, this 
experiment did not work, and no transcription factor was seen as a possible 
candidate, but at that time we did not know about the HNF4alpha binding site 
on the proximal promoter of the gene and we hypothesized that in HeLa cells 
where those factors are not enough expressed, their co-expression with our 
construct will enhance the luciferase activity to a similar level than observed 
in HepG2.  
Our next step was that we should be able to identify the factor involved by 
using a DNA-protein interaction screening system, and in that purpose we 
needed to reduce the number of factor candidates and the size of the region. 
Thus we designed a luciferase construct containing a truncated HS3 (-
332/+652), and we compared its activity with the -332/+629 and -332/+688 
constructs. To rule out one protein candidate, we designed the new construct 
in such a way that the HNF3 binding consensus observed by in silico analysis 
was cut in two parts. Thus we expected a total loss of activity for the -
332/+652 construct if the enhancer was located in the +652/+688 region or 
was the HNF3 transcription factor. In contrast, if the enhancer protein binds to 
the +629/+652 region we expected a luciferase activity of the -332/+652 
construct similar to the -332/+688 construct.  
Surprisingly, we observed that the -332/+652 construct exhibits half of the 
activity observed with the -332/+688, but still 4 times more luciferase activity 
than the -332/+629 (Figure 38). This result can have two possible 
explanations: first it is possible that the +629/+688 region contains sites for 
multiple factors that act synergistically or additionally, or the +652 site is in 
the middle of a transcription factor binding site and cuts it in two parts that can 
still partially bind the factor, leading to a partial decrease in the luciferase 
activity  
 
Figure 38. HS3 mapping. Different luciferase constructs were transiently transfected to 
HepG2 and Caco2 cells. Results of the assay were standardized against control reporter 
activity (pCMV-SEAP) and expressed as fold induction over control value (activity of the 
empty vector pGL3-basic), mean±SE (n = 5), *p<0.05 
4.2.7 The HS3 enhancer is interacting with the -234/-209 region in 
the proximal promoter of the ABCC6 gene. 
In our last set of experiments we investigated the relation between the HS3 
and the proximal promoter of the ABCC6 gene. Previously we demonstrated 
that the HS3 was linked to the -332/-145 region in the promoter of the ABCC6 
gene, and that the proximal promoter of the gene contains a HNF4alpha 
binding site under the negative regulation of the ERK1/2 cascade. We 
hypothesized that the HS3 is linked to the HNF4alpha binding site. To confirm 
this hypothesis we first investigated the possible modulation of the -332/+960 
luciferase activity after treatment with PMA as an inducer of the ERK1/2 
kinase cascade and with U0126 as an inhibitor of this cascade. We observed a 
70% inhibition after treatment with PMA, while treatment with U0126 led to 
an activation of approximately 160% of the -332/+960 luciferase activity 
(Figure 39). We previously demonstrated that the ERK1/2 cascade is 
inhibiting the expression of the ABCC6 gene via a negative modulation of 
HNF4alpha, then this result showed that the enhancer activity of the HS3 is 
modulated as well by the ERK1/2 cascade suggesting that the HS3 enhancer is 
linked to the HNF4alpha binding site.  
 
Figure 39. The HS3 is sensitive to the ERK1/2 modulation via the proximal promoter of the 
ABCC6 gene. The construct containing HS1, HS2 and HS3 (-332/+960) was transiently 
transfected to HepG2 cells. 24 hour after the transfection cells were treated with PMA or 
U0126 at the indicated concentrations or vehicle. Cells were treated with the compounds for 
24 hours and promoter activity was then measured by luciferase assay. Results of the assay 
were standardized against control reporter activity (pCMV-SEAP) and expressed as fold 
induction over control value (activity of empty vector (pGL3-basic) in control treated cells), 
mean±SE (n = 5), *p<0.05.  
To further confirm this link, we designed two supplementary constructs           
-234/+688 and -209/+688 and we compared their luciferase activity in HepG2 
and Caco2 cells, with the already described -332/+68 construct. As expected 
the -332/+688 and the -234/+688 constructs showed a similar important 
activity, since all three HS sites were present. More interestingly the -
209/+688 construct showed a low luciferase activity comparable to the -
145/+688 activity observed previously (Figure 40), showing that the HS3 
enhancer is interacting with the -234/-209 fragment and not with the 
HNF4alpha factor as previously suspected.  
 
Figure 40. HS3 is interacting with the -234/209 region of ABCC6 proximal promoter. 
Different luciferase constructs were transiently transfected to HepG2 and Caco2 cells. Results 
of the assay were standardized against control reporter activity (pCMV-SEAP) and expressed 
as fold induction over control value (activity of the empty vector pGL3-basic), mean±SE (n = 
5), *p<0.05 
In conclusion we identified three hypersensitive sites, named HS1, HS2 and 
HS3, located respectively in the proximal promoter and the first intron of the 
ABCC6 gene. We assumed that the HS1 marks the HNF4alpha binding site in 
the proximal promoter of the ABCC6 gene. We also showed that the HS2 has a 
role in the basal expression of ABCC6, and is connected with the -145/+72 
region representing the minimal proximal promoter of the gene. Last we 
demonstrated that these HS sites exhibit tissue specificity, and that the two 
intronic HS sites are acting as enhancers. Localization of the HS3 site 
identified a 60bp region that may contain more than one binding site for 
transcription factors. Finally, we demonstrated that the HS3 enhancer is 
connected to the -234/-209 region of the proximal promoter and has a crucial 
role in the enhancement of the transcription of the ABCC6 gene in tissues 
expressing the gene. Moreover, we showed that the transcriptional regulation 
of the ABCC6 gene is under a complex regulatory mechanism. Indeed in 
tissues expressing ABCC6, the HS3 enhances the expression of the gene and is 
dependent of the -234/-209 region that enhances the HNF4alpha activity 
(Figure 41). In contrast, in tissue non expressing ABCC6 the HNF4alpha is 
absent, and the gene expression is enhanced by the HS2, which is dependent 
of the -145/+72 region of the proximal promoter of the gene.  
 
Figure 41. Schematic presentation of the different element regulating ABCC6 expression and 
their interconnection. Arrows indicate connection/dependency between two elements.  
5  Discussion 
5.1 Introduction 
It has been shown that pseudoxanthoma elasticum (PXE), the Mendelian 
disease associated with loss-of-function mutations in the ABCC6 gene, is a 
metabolic disease (Jiang, Oldenburg et al.). We think that the metabolite 
involved in the disease can influence the regulation of the gene. Therefore 
understanding the regulation of the gene, and the different intracellular 
processes leading to its modulation can give clues about the role of this 
transporter.  
The goal of my PhD was to explore the regulation of the human ABCC6 gene. 
First by investigating the possible physiological mechanisms leading to the 
regulation of ABCC6 based on drug-screening analysis of actives molecules. 
With that strategy we revealed a mechanism of regulation of the ABCC6 gene 
expression involving the ERK1/2 cascade and the HNF4alpha transcription 
factor. Second by exploring the different regulatory sites present in the natural 
chromatin structure by using the DNase I hypersensitive assay. This method 
allowed us to highlight an enhancer element in the first intron of ABCC6, 
which acts with the HNF4alpha factor and dramatically increases the 
expression of the gene. 
5.2 Choice of the techniques 
In the great variety of techniques options to study gene transcriptional 
regulation, we chose first dug screening. Indeed we consider this technique as 
the first step in understanding the basic regulation of a gene. In parallel we 
decided to investigate the possible regulatory elements present on the genomic 
DNA sequence of the gene by using the DNase I hypersensitive assay. The 
choice of this technique was made in order to screen the region in a hypothesis 
free context. Our idea was to obtain independent results from both techniques, 
in order to have a better overview of the ABCC6 gene expression regulation.  
These techniques do not give that much information by themselves and need 
to be completed by other studies to obtain a comprehensive picture of the gene 
regulation. In that purpose we chose the luciferase assay technique. The major 
arguments for the choice of this technique were the multiple possibilities that 
allow the transfection of cells (from the simple luciferase vector transfection, 
to co transfection of the vector with transcription factor of interest), as well as 
the fact that this technique is considered as a reference technique in the study 
of the transcriptional regulation.  
Finally, the last step of transcriptional regulation studies is usually the 
confirmation of the binding of the identified factor on the DNA sequence. For 
that two techniques are mainly used, the EMSA or the ChIP experiments, that 
both can reveal DNA-protein interaction. EMSA fish out the protein 
interaction with a selected sequence by reproducing the possible interaction in 
vitro, adding to the tested sequence the selected protein, and looking for a shift 
in the DNA migration in the case of interaction between the protein and the 
DNA. The other technique, the ChIP allows the confirmation of a DNA-
protein interaction by immunoprecipitation of a selected protein bound to any 
DNA sequence where the factor is binding. Then the DNA-protein interaction 
is confirmed by PCR analysis of the DNA fragments co-immunoprecipitated. 
In our experiments we chose to perform the ChIP assay. Indeed, we believe 
that the results obtained with this technique are more representative of the 
physiological state of the cells, and ChIP has been more and more recognized 
during the last years as the reference technique to study protein DNA-
interaction. 
5.3 Cell lines 
We first chose the in vitro system that we wanted to use for the different parts 
of the study. We know from the literature that the ABCC6 gene is mainly 
expressed in the liver and in a lower extent in the kidney and the intestine 
(Kool, van der Linden et al. 1999). Therefore we started looking for relevant 
cellular models of these tissues, and first for a good cellular model of the 
hepatic tissue. We compared the two more frequently used hepatoma cell lines 
available in the ATCC cell catalogue, the HepG2 and the Hep3B. Both cell 
lines are used as liver models in different studies, but after investigating and 
comparing their characteristics in the literature and on the ATCC catalogue we 
noticed that the Hep3B cell line is infected by the Hepatitis B virus, therefore 
we chose the HepG2 cells. Since ABCC6 has also been shown to be expressed 
in the intestine at a low but detectable level, we looked for a cellular model of 
this tissue. The Caco2 cells seemed to be the perfect model since it is highly 
used in the literature as intestinal model for drug studies. We first 
demonstrated a high expression of the ABCC6 gene in this model, and we 
therefore decided to use it to study ABCC6 transcriptional regulation, showing 
for the first time that ABCC6 can be studied in this cell line. Finally we chose 
two cell lines that express ABCC6 at very low level, the HEK and the HeLa 
cells. It is somehow surprising for the HEK that is originated from a kidney 
where ABCC6 is normally expressed, but it is important to stress here that 
HEK cells are derived from an embryonic kidney where ABCC6 is barely 
detectable (Beck, Dang et al. 2005), which can explain our choice.  
5.4 HNF4alpha-ERK1/2 axis modulates ABCC6 expression 
5.4.1 Background 
Previous reports showed that ABCC6 transcriptional regulation was under the 
modulation of various factors, such as NF-kB, RXR, SP1 and PLAG (Jiang, 
Matsuzaki et al. 2006) (Ratajewski, Bartosz et al. 2006) (Ratajewski, Van de 
Ven et al. 2008) (Ratajewski, de Boussac et al. 2009). But interestingly the 
physiological context of this regulation has never been studied. Here we 
demonstrated for the first time the involvement of the ERK1/2 physiological 
cascade in the regulation of the ABCC6 gene expression. Furthermore we 
showed that the ERK1/2 cascade is inhibiting the transcriptional activation of 
ABCC6 by modulating the HNF4alpha transcription factor. 
5.4.2 ABCC6 expression and the ERK1/2 cascade. 
Surprisingly our initial drug screening for molecules modulating ABCC6 
revealed that all the drugs tested had no, or only inhibitory effect, on the 
expression of the ABCC6 gene. We interpreted that as a result of a high basal 
expression of ABCC6 in the HepG2 cell line preventing us to find any 
inducers of the ABCC6 expression (Table1). This hypothesis was later 
supported by ChIP with the high basal binding of HNF4alpha on the ABCC6 
promoter (Figure 21). 
By investigating the remarkable effect of the growth factors on ABCC6 
expression and the effect of the different cascades activated by the binding of 
HGF to its receptor (You and McDonald 2008) (Kermorgant and Parker 
2005), we clearly emphasized the major role of the ERK1/2 cascade in the 
regulation of the ABCC6 gene expression. Several lines of evidence suggested 
that. First the ERK1/2 specific inhibitor U0126 induced ABCC6 expression, 
while similar experiments performed with its biologically inactive 
stereoisomer U0124 remained ineffective. Moreover, inhibition of the ABCC6 
expression by HGF or EGF was totally prevented by co-treatment with U0126 
(Figure 5 and 7). Second, the inhibitory effect of the vitamin K3, a strong 
oxidative stress inducer (Czaja, Liu et al. 2003), as well as other molecules 
inducing oxidative stress, were also partially prevented by co-treatment with 
U0126 (Figure 8). Thus, various stimuli leading to the activation of the 
ERK1/2 pathway had similar inhibitory effect on the ABCC6 gene expression, 
strengthening the important role of this cascade on the ABCC6 gene 
regulation. Third, we demonstrated a correlation between the ERK1/2 
phosphorylation/activation and the inhibition of the ABCC6 gene expression. 
Finally, co-transfection of a wild type promoter construct of ABCC6 with a 
constitutively active MEKK1 mutant (MEKK1ca) reduced the luciferase 
activity, while a co-tranfection with a dominant negative ERK1 (ERK1dn) 
mutant increased it. Both factors acted in a dose dependent manner 
emphasizing the role of ERK1/2 in the regulation of ABCC6 (Figure 14). 
5.4.3 The PKCs and the ERK1/2 cascade 
We also showed that the PKCs are involved in the regulation of ABCC6. Our 
results pointed out that PKC regulatory effect on the ABCC6 gene is 
dependent on the ERK1/2 cascade. Indeed ABCC6 inhibition by PMA 
treatments was insensitive to the specific PKC inhibitor BIMI while co-
treatment of PMA and U0126 led to the prevention of the inhibitory effect 
(Figure 4 and 5). Also, BIMI is known to inhibit two subfamilies of the PKCs, 
while the third one, the atypical subfamily, is resistant to the BIMI treatment 
(Reyland 2009). Moreover, it is also known that the atypical subfamily can 
activate the MEK1/2 cascade, by interacting with the Ras kinase, responsible 
for the MEK1/2 kinase phosphorylation/activation. Finally, it is known that 
PKC can down modulate the HNF4alpha factor. Our ChIP assay results 
showing a similar loss of binding of HNF4alpha on the proximal promoter of 
ABCC6 after treatment with HGF or PMA suggest that PKC acts via the 
ERK1/2 kinase cascade. Altogether, these data strongly suggest the role of the 
four atypical PKC isoforms in the regulation of the ABCC6 human gene. 
5.4.4 ERK1/2 and oxidative stress. 
The different oxidative stress inducers clearly inhibited the expression of the 
human ABCC6 gene at the transcriptional level as we observed. Since there is 
a link between the oxidative stress and the induction of the ERK1/2 cascade 
(Ref. Czaja 2003) we tested the possibility that the observed ABCC6 
expression inhibition was due to ERK1/2 by performing co-treatment with the 
ERK1/2 specific inhibitor U0126. Our results only showed a partial prevention 
of the inhibition in presence of U0126 (Figure 8) suggesting that the observed 
effect was only partially due to the activation of the ERK1/2 cascade. That 
hypothesis was confirmed by performing a western blot to detect the ERK1/2 / 
ERK1/2-P ratio after treatment with selected compounds (Figure 9). Although 
we repeated this experiment, each time a high background prevented us to 
analyze the immunoblot by densitometry. However, this result emphasized the 
fact that we were not able to rule out another mechanism of inhibition of the 
gene expression by the oxidative stress and we did not investigate further the 
possible mechanisms involved. Nevertheless we also tested oxidative 
treatment performed on the -332/+72 construct in HepG2 cells. Surprisingly, 
these treatments did not inhibit the luciferase activity of the ERK1/2 sensitive 
-332/+72 construct (not shown) suggesting that oxidative stress inhibits the 
expression of the ABCC6 gene via an alternative, unknown mechanism than 
the ERK1/2-HNF4alpha axis. To confirm that, a ChIP experiment screening 
for the binding of HNF4alpha on the proximal promoter of the gene after 
treatment with the oxidative stress inducers need to be done. 
5.4.5 Erk1/2 regulates ABCC6 via the -209/-145bp region. 
After dissecting the role of the ERK1/2 cascade in this regulation, we 
investigated the inhibitory mechanism at the molecular level. We first proved 
that ERK1/2 regulates ABCC6 expression at the transcriptional level using the 
alternative transcript of ABCC6 called URG7 (which has the same 5’part as 
the ABCC6 gene) (Lian, Liu et al. 2001) (Figure 10 and 11). Based on these 
data we performed luciferase reporter gene assay to identify and characterize 
the ERK1/2 response element in the ABCC6 promoter. We observed a cell 
type specific response of the ABCC6 wild type promoter to the ERK1/2 
pathway activation (Figure 13 and 15). We located the ERK1/2 response 
element between -209 and -145bp from the translation initiation site (Figure 
17). This finding was in accordance with our previous findings showing that a 
tissue specific factor is binding to the proximal promoter of the gene 
(Ratajewski, de Boussac et al. 2009). We previously demonstrated that this 
element is stabilized by the PLAG transcription factor and is binding to the -
165/-150 region. As the m1 construct containing mutated PLAG binding site 
remained responsive to the ERK1/2 cascade activation, we ruled out PLAG as 
possible target of the ERK1/2 cascade. 
5.4.6 Post transcriptional regulation of ABCC6 
Cycloheximide (CHX), a protein synthesis inhibitor, was the only treatment 
where we observed a different ABCC6 and URG7 expression modulation. 
ABCC6 was significantly up-regulated by CHX treatment alone, while the 
URG7 transcript was down-regulated (Figure 12).  
It is known that post transcriptional regulations often occur on the 3’part of the 
mRNA, and we know that ABCC6 and URG7 transcript only share their 5’ 
part (Figure 10). Since the two transcripts do not react equally following CHX 
treatment, we hypothesized that they have a different post-transcriptional 
regulation, consequence of a protein with a short turnover that binds to the 
ABCC6 transcript and destabilize it. Then our observation was due to the fact 
that cycloheximide treatment stopped the de novo synthesis of this protein 
leading to an increase in the ABCC6 mRNA level.  
Finally we also studied the half life of the transcripts and we observed an 
important differences between ABCC6 and URG7 since ABCC6 half life was 
found at approximately 6 hours while the URG7 half life was found at more 
than 22 hours (not shown), confirming the difference in mRNA stability of the 
two transcripts and their post-transcriptional regulation differences. Moreover, 
RTqPCR performed to measure ABCC6 and URG7 also revealed a 100fold 
difference between both transcripts, result of their mRNA stability difference. 
Nevertheless, even if the analysis is complicated by the post-transcriptional 
differences, our results suggest that de novo synthesis of a protein is not 
required for the ERK1/2 inhibition of ABCC6. Indeed even if CHX alone lead 
to a difference in the transcript stability, when we performed co-treatment of 
CHX and PMA, we observed similar inhibitory effect for the URG7 and the 
ABCC6 expression (see bellow the section 5.4.8).  
5.4.7 HNF4alpha 
In silico search performed on the -165/-150 identified region strongly 
suggested us that HNF4alpha might be a good candidate for binding to this 
sequence (Figure 18). A number of reasons gave credit to that idea. First, 
HNF4alpha is known to have a strong tissue specificity that overlaps with 
ABCC6’s expression pattern (Sladek, Zhong et al. 1990) (Kool, van der 
Linden et al. 1999). Second a recent study with HNF4alpha microarray 
identified a binding site at -166/-154bp of the ABCC6 promoter, and siRNA 
against HNF4alpha significantly decreased the expression of the ABCC6 gene 
in HepG2 cells (Bolotin, Liao et al.). Also, another group identified, by ChIP-
on-chip analysis, the ABCC6 promoter as a target for the HNF4alpha 
transcription factor (Odom, Zizlsperger et al. 2004). Finally, the predicted 
sequence shows a high degree of evolutionary conservation (14 in a block of 
16 nucleotides are identical in four species) (Aranyi, Ratajewski et al. 2005) 
and HNF4alpha has already been proposed to have a role in the regulation of 
the murine ABCC6 gene, where it acts on the same evolutionary highly 
conserved site (Douet, VanWart et al. 2006). All these data point to the 
potential role of HNF4alpha in the ERK1/2 dependent regulation of the 
ABCC6 gene. 
To confirm that hypothesis we performed experiments in HeLa cells that do 
not express the HNF4alpha transcription factor. In this cells co-transfection of 
the HNF4alpha transcription factor and the luciferase promoter construct 
resulted in a similar level of activity than observed in the HepG2 cells (Figure 
20). On the contrary the introduction of a mutation in the HNF4alpha binding 
site destroyed the luciferase activity when co-transfected with HNF4alpha. 
suggesting that the HNF4alpha is responsible for the cell specific expression 
of the gene. Supported by these evidences, and the overlapping of ABCC6 and 
HNF4 expression in the tissues we also believe that HNF4alpha is responsible 
for the tissue specific expression of the ABCC6 gene. 
5.4.8 ERK1/2 and HNF4alpha 
After demonstrating that HNF4alpha is responsible for ABCC6 tissue specific 
expression, we confirmed the link between HNF4 and the ERK1/2 cascade. 
By co-expressing HNF4alpha and MEKK1ca in HeLa cells (Figure 20), 
suggesting that ERK1/2 is modulating the expression of ABCC6 via the 
regulation of HNF4alpha. 
The result of the ChIP experiment showing a decrease in the binding of 
HNF4alpha after ERK1/2 activation in HepG2 cells (Figure 21) further 
supported the regulation of HNF4alpha by the ERK1/2 cascade. This could be 
interpreted as a decrease in the affinity of HNF4alpha for the promoter, or as a 
decrease in the HNF4alpha protein total amount, and finally it is also possible 
that the antibody used in this experiment cannot recognize a phosphorylated 
HNF4alpha, and that the transcription factor is present on the promoter but is 
inactivated.  
It has been shown that HNF4alpha is under the control of PKA or PKC (Sun, 
Montana et al. 2007) (Viollet, Kahn et al. 1997), and few studies investigated 
the role of the ERK1/2 cascade in the regulation of HNF4alpha. Indeed, Reddy 
et al. and Hatzis et al. demonstrated that the HNF4alpha promoter is sensitive 
to the ERK1/2 cascade. The ERK1/2 activation leads to a decrease in the 
amount of HNF4alpha mRNA translated into a decrease in the protein amount 
(Reddy, Yang et al. 1999) (Hatzis, Kyrmizi et al. 2006).  
In our system in HeLa cells, HNF4alpha is expressed under a CMV promoter, 
thus it is unlikely that the HNF4alpha is regulated by ERK1/2 at the 
transcriptional level. Therefore, in our case, the ERK1/2 cascade seems to 
modulate the activity of HNF4alpha protein directly and not to regulate its 
protein amount (this is in accordance with the CHX treatment results, see 
above 5.4.6). On the other hand, we cannot rule out the possibility of a double 
regulation of HNF4alpha (both the gene expression level and the protein 
activity level) in the HepG2 cell line where endogenous HNF4alpha is 
expressed.  
All these elements point out the convincing hypothesis of the ERK1/2 cascade 
modulating the HNF4alpha activity, most probably via phosphorylation. 
Indeed, a study showed that phosphorylation of HNF4alpha can lead to a 
distinct subnuclear localization than normally observed (Ktistaki, Ktistakis et 
al. 1995).  
5.4.9 HNF4alpha and other ABCC transporters 
HNF4alpha has already been proposed to have a role in the regulation of the 
human ABCC2 gene (Qadri, Iwahashi et al. 2006) (Qadri, Hu et al. 2009). We 
were not able to reproduce the results of that study, and our data do not 
suggest any involvement of the ERK1/2 cascade in ABCC2 expression 
regulation since treatment of HepG2 cells with HGF or co-treatment with 
HGF and U0126 induced the expression of ABCC2 in our hands (not shown). 
Moreover our data about oxidative stress confirmed the differences between 
the regulation of ABCC6 and ABCC2. It is then possible that ABCC6 
regulation by the ERK1/2-HNF4alpha system is limited to ABCC6, and that 
other factor(s) is/are needed to stabilize HNF4alpha on the genomic DNA. 
This would explain the difference in expression observed at the mRNA level 
between ABCC6 and ABCC2. 
5.4.10 Perspectives 
Under physiological circumstances in resting hepatocytes, the ABCC6 gene 
expression reaches its highest level, and the ERK1/2 pathway has a low basal 
activity that contributes to the attachment of the cells to each other. However, 
ERK1/2 is known to be activated by a multitude of signals (e.g. growth 
factors, G protein coupled receptors) during cell growth, and cell division. It is 
likely to think that ABCC6 gene expression decreases in these conditions. 
Similarly, in oxidative stress conditions in hepatocytes, the ERK1/2 cascade is 
activated, and we showed that ABCC6 gene expression is sensitive to that 
signal. This suggests that although in the absence of functional ABCC6, which 
leads to the development of PXE, chronic oxidative stress was observed in 
dermal fibroblast and other cell types (Pasquali-Ronchetti, Garcia-Fernandez 
et al. 2006); the physiological role of MRP6 may not be the protection of the 
cells from the oxidative stress. Since vitamin K3 strongly inhibited the 
expression of the gene it seems to be unlikely that vitamin K3 itself or one of 
its derivatives would be the most important physiological substrate of the 
MRP6 protein, in contrast to a current hypothesis (Borst, van de Wetering et 
al. 2008). 
5.5 Identification of an enhancer in the first intron  
5.5.1 Introduction 
Transcriptional regulation is a highly complex mechanism involving multiple 
aspects of the regulation from DNA methylation to transcription factor binding 
to the promoter. Transcriptional regulation of the ABCC6 gene has previously 
been studied using drug screening, luciferase assay and DNA/protein 
interaction detection techniques. We further analyzed the human ABCC6 
regulation by investigating the role of the chromatin environment using an 
alternative technique. 
5.5.2 DNase I set up 
The DNase I assay technique is an efficient tool used to reveal gene regulatory 
regions as active promoter or enhancer (Wu, Bingham et al. 1979). Enhancers 
have been shown to be located either very far from the gene they modulate, or 
also sometimes in the first introns of the genes (Hines, Mathis et al. 1988) 
(Smith, Barth et al. 1996). This last observation led us to investigate a 10kb 
upstream region from the ATG together with the first intron of the ABCC6 
gene. Accordingly we designed the probe (P61) and we chose the restriction 
enzymes in order to be able to visualize and analyze these regions. After the 
observation of the first HS sites by Southern blot we designed a second probe 
P62 at the end of the first intron of the ABCC6 gene to locate the identified HS 
(Figure 28). We had several arguments to do so. First, we wanted to locate 
more precisely the HS revealed with P61. Therefore the intronic region was 
the best choice to design a new probe, in order to be able to locate precisely 
the HS site located close to the ABCC6 ATG. Furthermore, as I previously 
mentioned, the first intron of genes are regions where HS sites can be 
observed. Finally, the first intron of ABCC6 does not contain repetitive 
elements. 
5.5.3 Identification of the HS sites and significance of the HS1  
By using P62 in Southern blot, we clearly observed a hypersensitive band that 
we were able to locate in the proximal promoter of the ABCC6 gene around 
the previously identified HNF4alpha binding site, and two other HS in the first 
intron of ABCC6 (Figure 30 and 31). We first considered the HS1 as a mark of 
open chromatin structure linked to the presence of the HNF4alpha 
transcription factor. Independent clues led us to that conclusion. First, HS 
marks active regions of promoters and we demonstrated the important role of 
HNF4alpha in ABCC6 regulation (see Figure 22), the location of the HS1 is in 
accordance with the binding site of HNF4alpha. Moreover, we observed a 
tissue specific pattern of the three identified hypersensitive sites including 
HS1 (Figure 33). Since HNF4alpha has the same pattern of expression as HS1 
this other evidence emphasized the connection between the HS1 and the 
HNF4alpha binding site. However, we also identified different regions of the 
proximal promoter that harbored transcriptional activity. We demonstrated 
that the -145/+72 region has a basal activity (Figure 35), while the -209/-145 
region shows tissue specific activity due to the presence of the HNF4alpha 
transcription factor, and finally the -234/-209 region is connected to the 
HNF4alpha and the HS3 site (Figure 40). These new evidences made us think 
that the HS1 might represent the -332/-145 region activity instead of only a 
part of it.  
5.5.4 Tissue specificity and HS1 
The tissue specificity observed with the construct containing the three 
hypersensitive sites is most probably due to the presence of the HS1 in the 
construct. Indeed, the -145/+72 (as the -145/+629) construct does not show 
any tissue specific activity since it harbors an equivalent activity in different 
cell types (Figure 35). On the other hand construct containing the HS1 site 
exhibit tissue specific activity (Figure 33). It is probable that the tissue 
specificity observed with the construct containing the HS3 enhancer is due to 
the presence of the HNF4alpha factor in the proximal promoter. Nevertheless 
we have no data about the tissue specificity of the factor(s) binding to HS3, it 
is then possible that this/these factor(s) is/are more widely expressed, and that 
the presence of HNF4alpha determines the tissue specificity, or that these 
factors are tissue specific as the HNF4alpha.  
5.5.5 Role of HS2 
Investigating the two other HS sites highlighted the interesting effect of HS2. 
We demonstrated that HS2 seems to have a role in the basal expression of the 
gene. Indeed the luciferase activity of -145/+629 demonstrated an increase in 
comparison with the -145/+72bp construct (Figure 36). We can’t clearly 
conclude on the role of HS2, but we assume that the factor, or the element 
revealed by DHA interacts with the -145/+72 region of the ABCC6 gene, and 
it leads to the enhancement of the minimal promoter activity. It has been 
shown that Sp1 and RXR can bind to this region of the promoter (Ratajewski, 
Bartosz et al. 2006) (Jiang, Matsuzaki et al. 2006), therefore it is possible that 
the HS2 is acting synergically with one or both of these factors. 
It should also be noted that the presence of the -234/ -145 region hides the 
effect of HS2 on the minimal promoter. Indeed, the luciferase activity of the -
332/+72 construct is equivalent to the activity of the -145/+629 and the -
145/+688 constructs (Figure 36). Similarly, the -209/+688 construct exhibits 
equivalent activity than the -145/+688 while the -234/+688 has the maximum 
luciferase activity (Figure 40). This observation suggests that the presence of 
HNF4alpha itself is not sufficient for the hiding effect of -234/-145 on HS2. 
Our data indicate that the presence of the factor binding to the -234/-209 
region is required for that effect. 
With our current understanding we cannot explain this mechanism completely, 
It is possible that the recruitment of the HNF4a transcription factor, together 
with the unidentified factor binding to the -234/-209 region, leads to the 
release of the factor(s) binding on the minimal promoter, therefore preventing 
the enhancement of HS2 on the construct. Moreover the interaction of the -
234/-209 region with HS3 may also lead to the release of the factor binding on 
the -145/+72 region. 
5.5.6 Role of HS3 
The most interesting hypersensitive site that we found was undoubtedly HS3. 
We believe that this element enhances the expression of the ABCC6 gene, and 
different indications meet up with this hypothesis. First, the addition of HS3 to 
the two other hypersensitive sites leads to a dramatic increase in the luciferase 
activity if compared to the HS1 or the HS1+HS2 constructs (Figure 33). We 
also ruled out the possibility of the presence of a second promoter in the first 
intron by designing a construct containing HS3 alone, and we couldn’t observe 
any luciferase activity (Figure 34), showing that this element cannot act on its 
own, and thereby it should be considered as an enhancer. 
5.5.7 Factors binding to HS3 
It is very difficult to predict the binding of a protein on a DNA sequence if this 
one is too long. Furthermore, the predictions of factor binding sites are not 
taking into account the cellular environment and the reality of the regulation. 
In order to identify the location of HS3 we narrowed down the functional part 
of this element by cloning different sizes of the region, and we identified the 
+629/+688bp region as the core containing the binding site (Figure 33).  
We then performed in silico analysis of the HS3 site (Figure 37) but to be 
certain to do not miss the possible candidate we increased the size of our HS3 
sequence. Indeed it is possible that the position +629, which marks the 5’end 
of the HS3 region, is part of a binding site. In such a case the -332/+629 
construct would behave as a mutated construct of this hypothetical site. 
Inversely the -332/+688 construct harbored a full activity showing that any 
potential binding sites are located 5’ of the +688 position. Consequently, for 
the in silico analysis of this region we incorporated ten base pairs on the 5’ 
part of the sequence to include any potential supplemental binding site. 
In silico analysis gave us potential candidates for this 60bp region and we 
tested them by cotransfection with the -332/+688 construct in the HeLa cells 
(not shown). Not surprisingly with our current knowledge none of the 
transcription factors was able to increase the luciferase activity of our -
332/+688 construct. However, at this time we have not yet identified the 
HNF4alpha factor as responsible for the tissue specific expression of the gene, 
and we thought that the tissue specific expression of the ABCC6 gene was due 
to the binding of a tissue specific factor on HS3. Then we expected an 
enhancement of the luciferase activity in HeLa cells after that co-transfection.  
Since we did not obtain any results with the co-transfection assay, we decided 
to narrow down the HS3 site in order to limit the number of possible binding 
factors to the sequence using the -332/+652bp constructs (Figure 38). We 
observed a 50% decrease of the luciferase activity for the -332/+652 construct 
compared to the -332/+688. To explain this surprising result, and since activity 
of the -332/+652 construct was still four times more important than the -
332/+629, we hypothesized that more than one factor can bind to the -
629/+688, and then a factor is binding to the +629/+652 and another one to the 
+652/+688 region. Alternatively, it is possible that only one factor binds to 
HS3. Indeed, the -332/+652 construct truncates the HNF3 binding site present 
in this region, which can lead to a partial binding of the factor and therefore a 
partial activity of the construct. Therefore, we still consider HNF3 as a 
potential candidate for the binding to the HS3 site. To verify that hypothesis 
we are currently co-expressing HNF4alpha, the selected transcription factor 
and our -332/+688 construct in HeLa cells.  
5.5.8 A unified view 
We investigated the regulation process of the ABCC6 gene expression, and our 
results showed the complexity of this regulation. We demonstrated that the 
HS2 enhancer located in the first intron of the gene is acting on a basal 
promoter located between -145/+72bp. The presence of this basal promoter in 
every cell type, is suggesting a minimal expression of ABCC6 in tissues 
different than the liver. However, when we compared the amount of transcript 
between HepG2 and HeLa, we observed a 200-fold difference while only 7 
fold difference was observed in the luciferase activity between he -145/+629 
(minimal promoter + HS2) and the -332/+688 (tissue specific) constructs. 
Moreover tissue specific methylation of the proximal promoter of the ABCC6 
gene was previously observed. It is therefore possible that the basal promoter 
observed in luciferase has no significant effect in the cells but we cannot 
conclude on the relevance of this observation. A possible explanation of the 
basal expression of ABCC6 in other tissue could be a role of the protein in 
detoxification processes, acting in parallel with other ABC transporters, but in 
that case the presence of the protein need to be confirmed. 
Finally, we described different regulatory element of the ABCC6 gene 
expression and we demonstrated the connections existing between them 
(Figure 42).  
 
Figure 42.Synthetic scheme representing the different element regulating ABCC6 expression 
and their inter-connection. Arrows indicate connection/dependency between two elements. 
ERK1/2 down-modulates the HNF4alpha activity. 
We showed that HNF4alpha is a key mediator of the tissue specific expression 
of ABCC6. We proved that the HS3 enhancer is dramatically increasing the 
expression of the gene by interacting with the -234/-209 region of the 
proximal promoter, and we believe that this region needs the presence of the 
HNF4alpha transcription factor to be active.  
In conclusion we described a complex regulatory mechanism of the ABCC6 
gene expression, leading to tissue specificity and involving the presence of 
different factors for a full ABCC6 expression in tissue expressing the gene. 
In this study we pointed out different regulatory elements of the ABCC6 gene 
expression, and we think that this may have consequences with respect to 
PXE.  
Indeed some of the PXE-causing ABCC6 mutations may result in only partial 
loss of function of the protein. Induction of expression of such a low activity 
mutant – in theory – could potentially be therapeutic in these cases. The 
induction of ABCC6 expression could be achieved at distinct levels: increased 
transcription, increased RNA stability or increased protein stability. However, 
we have almost no information to date about the regulation of ABCC6 RNA 
and protein stability. Therefore, currently the only way to develop a 
hypothesis-driven therapy based on increased ABCC6 expression is to 
intervene at the transcriptional regulation of the gene. As we showed, the role 
of ERK1/2-HNF4 pathway has been analyzed in a potential physiological 
context. As previously mentioned, HNF4 is a bona fide activator of the gene, 
while the activation of the ERK1/2 pathway inhibits HNF4 and thereby the 
expression of ABCC6. Moreover the future identification of the enhancers will 
also give more potential drug targets for a hypothetical treatment. 
However, from this study, an option to increase the expression level of the 
ABCC6 gene would be the inhibition of ERK1/2 activation in hepatocytes. 
Due to the myriad of ERK1/2 activating factors, the low basal activity and the 
fast turnover of the signals, inhibitory stimuli of ERK1/2 are not easy to find. 
Some of the anticancer therapies are targeting the ERK1/2 pathway and 
promising results have been obtained both in vivo and in vitro in inhibiting 
cancer progression (Roberts and Der 2007) (Friday and Adjei 2008), It is 
highly probable that new generations of these molecules will become 
available. These molecules might have beneficial effect in some patients 
because only a slight inhibitory effect would be necessary in the case of PXE 
symptoms, the toxic effect of the molecules on other tissues would be 
diminished. Furthermore, in some cases patients are suffering from chronic 
oxidative stress and develop secondary PXE (e.g. in beta thalassemia) 
(Hamlin, Beck et al. 2003). These patients treated with ERK1/2 inhibitors 
and/or an anti-oxidative stress therapy might also receive therapeutic benefit. 
Similarly, the ABCC6 mutation carriers also suffer from mild oxidative stress 
(Pasquali-Ronchetti, Garcia-Fernandez et al. 2006) (Zarbock, Hendig et al. 
2007), a condition potentially inhibiting the expression of the gene from the 
remaining allele. These patients could presumably benefit from the same 
therapy to prevent the development of CAD. 
ERK1/2 has a wide variety of targets. One of them is HNF4, which is 
inactivated either directly or indirectly by the kinase (Reddy, Yang et al. 1999) 
(Hatzis, Kyrmizi et al. 2006). We have found that HNF4 transcription factor is 
a major regulator of the expression of ABCC6 and also a master regulator of 
metabolism in hepatocytes. By influencing the global metabolic state of the 
liver one can induce the expression and/or the activity of HNF4. Accordingly, 
it has been demonstrated that the functional HNF4 level is increased in fasting 
states in mouse (Martinez-Jimenez, Kyrmizi et al.). Similarly, it has been 
shown, that HNF4 is up-regulated by glucocorticoid hormones (Bailly, Torres-
Padilla et al. 2001). All these conditions might contribute to a higher ABCC6 
expression level and diminishing or eliminating the PXE symptoms in some 
PXE and probably the beta thalassemic patients.  
Approximately 10% of the PXE patients have no identified mutation, and we 
presume that some other patients do not have a complete loss of the 
ABCC6/MRP6 protein function. Therefore we can imagine that for these 
patients, increasing the expression of the gene by treatment targeting the factor 
involved in the gene regulation might decrease the severity of the PXE 
phenotype. Moreover it has been shown that heterozygous carriers have an 
increased risk in coronary artery disease (Koblos 2010, Trip 2002), and beta 
thalassemia patient can develop PXE-like symptoms (Hamlin beck 2003). 
These two groups may get benefits from a treatment to increase the ABCC6 
expression that may diminish the complication. Thus, according to this study, 
treatments activating HNF4alpha, or the HS3 enhancer, when it will be 
identified, would lead to ABCC6 expression induction, and then a reduction of 
the PXE associated phenotypes. Finally an other option would be to target the 
ERK1/2 cascade using specific inhibitors of this pathway that are available as 
anticancer drug, but the benefit effect may be less than the side effects.  
At last, open questions still remained, and are currently under investigation in 
our laboratory: what are the different factors binding in the +629/+688 and the 
-234/-209 regions? What is the mechanism of regulation of the RNA at the 
post-transcriptional level? Is there polymorphism related to the PXE disease in 
the HS3 region? 
 
6  Conclusions 
We have investigated the transcriptional regulation of the ABCC6 gene, using 
different techniques. By examining the gene modulation following treatment 
with various factors involved in major physiological pathway in the cells, we 
described that the ERK1/2 cascade inhibits its expression. Further analysis by 
luciferase reporter gene assay revealed that the proximal promoter of the gene 
contains the response element to the ERK1/2 cascade. Moreover we showed 
that ERK1/2 modulatory effect on the ABCC6 gene was cell type specific. 
Indeed while expression of ABCC6 in HepG2, which express the ABCC6 
gene, was sensitive to ERK1/2 modulation, no differences was observable in 
the HeLa cell line, which do not express ABCC6. This last observation led us 
to the conclusion that the ERK1/2 cascade must modulate a factor involved in 
the tissue specific expression of the gene. 
We then identified the response element and locate it between -166 and -
154bp from the transcription initiation site. This element was identified as a 
degenerate HNF4alpha binding site. Co-expression of HNF4alpha and the 
ABCC6 promoter construct in HeLa cells, showed that HNF4alpha is 
responsible for the tissue specific expression of ABCC6. Next we 
demonstrated that the ERK1/2 cascade is inhibiting the HNF4alpha induction 
of ABCC6. Indeed in HepG2 cells, a mutated construct for the HNF4alpha 
binding site did not react anymore the ERK1/2 modulation by drugs. 
Moreover co-expression of HNF4alpha and the mutated construct in HeLa 
cells showed similar results. A last set of experiment confirmed these results 
since co-expression of HNF4alpha and MEKK1ca in HeLa cells lead to the 
inhibition of the ABCC6 luciferase activity. Altogether these results 
emphasized the crucial role of HNF4alpha in the regulation of ABCC6 
expression, but also highlighted the potentially important role of the ERK1/2 
cascade in this modulation.  
We revealed an important mechanism of the ABCC6 regulation, and we 
wanted to further examine the possible different elements involved in this 
regulation. In that purpose we used the DNase I hypersensitive assay 
technique that reveals open chromatin region, known to be located in active 
promoter or enhancer region. We identified four hypersensitive sites in a 12kb 
region nearby the translational initiation site of ABCC6. One was located in 
the first intron of the NOMO3 gene that is located close to the ABCC6 gene. 
More interestingly we identified three hypersensitive sites in a 4.5kb region 
around the ABCC6 translation initiation site and named from the 5’ to 3’ HS1, 
HS2 and HS3.  
We showed that HS1 is located in the proximal promoter of the gene, and that 
this hypersensitive site probably marks three active regions of the proximal 
promoter of the gene from 5’ to 3’, the -234/-209 region, the HNF4alpha 
binding site and the -145/+72 region.  
Next we described the HS2 in the first intron of the ABCC6 gene, and we 
showed that it enhances the activity of the minimal basal promoter of the gene 
located in the -145/+72 region. We demonstrated that the HS2 enhancer plays 
a role in the constitutive expression of the gene since the construct containing 
the HS2 and the minimal promoter do not exhibit any tissue specific pattern.  
Finally we demonstrated that the HS3 enhances dramatically the expression of 
the ABCC6 gene, and that this enhancement is dependent of the -234/-209 
region in the proximal promoter of ABCC6. We narrowed down the sequence 
containing the enhancer region to 60bp located in the first intron of ABCC6 in 
the +629/+688 region, and we determined that it is possible that more than one 
factor is binding to this sequence, but we were not able to identify the factor(s) 
involved. Altogether we identified crucial regions of the ABCC6 gene that are 
involved in its regulation, and we described for the first time the complex 
mechanism of regulation of this gene by demonstrating the interconnection 
between the different transcriptional regulatory elements present on the 
promoter and the first intron of ABCC6. 
7  Summary 
The ABCC6 gene encodes an organic anion transporter ABCC6/MRP6. It 
has been shown that mutations in the gene lead to the development of 
pseudoxanthoma elasticum a rare recessive genetic disease characterized by 
the calcification of elastic fibers. Although ABCC6 is mainly expressed in the 
liver, PXE symptoms are dermatologic, ocular and cardiovascular, which 
confirms the theory of a metabolic disease due to the lack of export in the 
blood of a liver specific metabolite. The transcription regulation of the gene 
has been studied but no physiological cascade has been described as a 
potential regulator of the gene. We believe that understanding the ABCC6 
gene regulation can lead to the understanding of the gene function and maybe 
the identification of the unidentified metabolite.  
Here we investigated the regulation of the gene using two different 
strategies. First by performing a drug screening we identified growth factors as 
potential inhibitor of the expression of the gene. We demonstrated that the 
ERK1/2 cascade is responsible for the inhibitory effect observed. Using 
luciferase reporter gene assay we showed that HNF4alpha is activating the 
expression of the gene and is responsible for its tissue specific expression 
pattern. We finally proved that the ERK1/2 cascade is down modulating the 
activity of HNF4alpha leading to the down regulation of the ABCC6 gene.  
Parallely, we investigated the transcription regulation of the gene in a 
hypothesis free context, using the DNase I hypersensitive assay. We identified 
three hypersensitive sites, and located HS1 in the proximal promoter and HS2 
and HS3 in the first intron of ABCC6. We characterized the functional role of 
these HS sites by luciferase assay. We demonstrated the enhancer activity of 
the intronics HS. HS2 acts on the minimal basal promoter of the gene mapped 
by luciferase between -145 and +72bp from the ATG in tissues where ABCC6 
is barely detectable. Finally we showed that HS3 enhances the expression of 
ABCC6 in tissues expressing the gene. The activity of HS3 is dependent on the 
presence of an unidentified factor binding to the -234/-209 region. The binding 
of this unknown factor depends on the presence of HNF4alpha. 
8  Összefoglalás 
Az ABCC6 gén egy organikus anion transzportert, az ABCC6/MRP6 fehérjét 
kódolja. A génben bekövetkező mutációk a pseudoxanthoma elasticum 
kialakulásához vezetnek, amely a rugalmas rostok meszesedésével járó ritka recesszív 
genetikai betegség. Bár az ABCC6 elsősorban a májban expresszálódik, a PXE tünetei 
a bőrben, szemben és a keringési rendszerben jeletkeznek. Ez igazolja a metabolikus 
betegség hipotézist, azaz hogy egy máj-specifikus metabolit vérbe történő 
exportjának a hiánya vezet a betegség kialakulásához. A gén traszkripciós 
szabályozását régóta vizsgálják, de még nem írtak le olyan fiziológiás kaszkád-
rendszert amely felelős lehet a gén szabályozásáért. Az ABCC6 gén szabályozásának 
a megértése hozzásegíthetne bennünket a gén funkciójának a megértéséhez, és talán a 
jelenleg még ismeretlen metabolit meghatározásához is. 
A gén szabályozásának tanulmányozása során két különböző stratégiát 
alkalmaztam. Először biológiailag aktív vegyületek szűrésével azonosítottam olyan 
növekedési faktorokat, amelyek lehetséges gátlószerei a gén expressziójának. 
Kimutattam, hogy az ERK1/2 kaszkád felelős a megfigyelt gátló hatásért. 
Azonosítottam egy konzervált HNF4alfa kötőszekvenciát és bizonyítottam, hogy az 
ERK1/2 hatás létrejöttéhez ez a szekvencia szükséges. További kísérleteimben 
igazoltam, hogy ehhez a szekvenciához a HNF4alfa kötődik, ami meghatározza a gén 
szövetspecifikus kifejeződését. Végezetül kísérleteim során megfigyeltem, hogy az 
ERK1/2 hatás a HNF4alfa transzkripciós faktor aktiváló hatásának szabályozásán 
keresztül jön létre.  
Ezzel párhuzamosan egy hipotézis-mentes megközelítéssel is vizsgáltam a gén 
transzkripciós szabályozását, a DNáz I hiperszenzitivitási esszét alkalmazva. Három 
hiperszenzitív helyet azonosítottam, a HS1-et a proximális promóteren lokalizáltam, a 
HS2-t és HS3-at pedig az ABCC6 első intronján. Ezt követően luciferáz esszével 
karakterizáltam ezeket a HS helyeket. Kimutattam az intronikus HS helyek enhancer 
aktivitását. Azokban a szövetekben, ahol az ABCC6 csak kis mértékben detektálható, 
a HS2 a gén minimál promóterén hat, amelyet luciferáz kísérleteimmel az ATG-től 
számított -145 és +72 bp közé térképeztem. Végül kimutattam, hogy az ABCC6-ot 
expresszáló szövetekben a HS3 növeli a gén expresszióját. A HS3 aktivitása függ egy 
még egyenlőre nem azonosított faktor jelenlététől, amely a -234/-209 régióhoz 
kötődik. Ennek az ismeretlen faktornak a kötődése pedig függ a HNF4alfa 
jelenlététől. 
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10   Abbreviations: 
ABC : ATP-binding cassette;  
ABCC6 : ATP-binding cassette protein, family C, number 6;  
AS : angioid streak;  
CAD : coronary artery disease;  
CGI : CpG island; 
ChIP : chromatin immunoprecipitation;  
CNV : choroidal neovascularization;  
DCC : dystrophic cardiac calcification;  
DHA : DNase I hypersensitive assay 
DHS : DNase I hypersnsitive site 
EGF : epidermal growth factor 
ERK1/2 : extracellular signal- regulated kinase 1/2;  
ERK1dn : ERK1 dominant negative mutant 
GGCX : γ-glutamyl carboxylase;  
HGF : hepatocyte growth factor 
HNF4 : hepatocyte nuclear factor 4;  
HS : hypersensitive site 
K3 : vitamin K3/menadione;  
KO : knock out;  
MAPK : mitogen-activated protein kinase;  
MEKK1ca : MEKK1 constitutively active mutant 
MRP : multidrug resistance-associated protein;  
PMA : phorbol miristate actetate 
PXE : pseudoxanthoma elasticum;  
RPE : retinal pigmented epithelium;  
tBHQ : tert-butyl hydroquinone 
VEGF : vascular endothelial growth factor;  
Wt : wild type. 
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